# EDGAR Filing Document

**Accession Number:** 0001417398
**File Stem:** 0001628280-26-006490
**Filing Date:** 2026-2
**Character Count:** 137145
**Document Hash:** e2afdeba80a2b9796dade3666524b3e8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-006490.hdr.sgml**: 20260209

**ACCESSION NUMBER**: 0001628280-26-006490

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 85

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260209

**DATE AS OF CHANGE**: 20260209

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Hillenbrand, Inc.
- **CENTRAL INDEX KEY:** 0001417398
- **STANDARD INDUSTRIAL CLASSIFICATION:** MISCELLANEOUS MANUFACTURING INDUSTRIES [3990]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 261342272
- **STATE OF INCORPORATION:** IN
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33794
- **FILM NUMBER:** 26612010

**BUSINESS ADDRESS:**
- **STREET 1:** ONE BATESVILLE BOULEVARD
- **CITY:** BATESVILLE
- **STATE:** IN
- **ZIP:** 47006
- **BUSINESS PHONE:** (812) 931-5000

**MAIL ADDRESS:**
- **STREET 1:** ONE BATESVILLE BOULEVARD
- **CITY:** BATESVILLE
- **STATE:** IN
- **ZIP:** 47006

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Batesville Holdings, Inc.
- **DATE OF NAME CHANGE:** 20071102

?xml version='1.0' encoding='ASCII'? hi-20251231

<u>[**Table of Contents**](#iffc0cdfc7e354fb28658de93fdd472c6_7)</u>

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

**FORM 10-Q** 

☒ **Quarterly Report Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**For the quarterly period ended December 31, 2025** 

**OR**

☐ **Transition Report Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**For the transition period from _____ to _____**

**Commission File Number. 001-33794** 

**HILLENBRAND, INC.** 

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Indiana** | **Indiana** | **26-1342272** |
| (State or other jurisdiction of incorporation or organization) | (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| **One Batesville Boulevard** | **One Batesville Boulevard** | |
| **Batesville,** | **IN** | **47006** |
| (Address of principal executive offices) | (Address of principal executive offices) | (Zip Code) |

---

**(812) 931-5000** 

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered <br> Common Stock, without par value HI New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ | Emerging growth company | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ | | |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The registrant had 70,656,607 shares of common stock, no par value per share, outstanding as of February 4, 2026.

------

<u>[**Table of Contents**](#iffc0cdfc7e354fb28658de93fdd472c6_7)</u>

**HILLENBRAND, INC.**

**INDEX TO FORM 10-Q**

---

| | | |
|:---|:---|:---|
| | | **Page** |
| | **<u>[PART I — FINANCIAL INFORMATION](#iffc0cdfc7e354fb28658de93fdd472c6_10)</u>** | |
| **<u>[Item 1.](#iffc0cdfc7e354fb28658de93fdd472c6_13)</u>** | <u>[Financial Statements (Unaudited)](#iffc0cdfc7e354fb28658de93fdd472c6_13)</u> |  |
|  | <u>[Consolidated Statements of Operations for the Three Months Ended December 31, 202](#iffc0cdfc7e354fb28658de93fdd472c6_16)[5](#iffc0cdfc7e354fb28658de93fdd472c6_16)[and 20](#iffc0cdfc7e354fb28658de93fdd472c6_16)[24](#iffc0cdfc7e354fb28658de93fdd472c6_16)</u> | [2](#iffc0cdfc7e354fb28658de93fdd472c6_16) |
|  | <u>[Consolidated Statements of Comprehensive Income](#iffc0cdfc7e354fb28658de93fdd472c6_19)[(](#iffc0cdfc7e354fb28658de93fdd472c6_19)[Loss)](#iffc0cdfc7e354fb28658de93fdd472c6_19)[for the Three Months Ended December 31, 202](#iffc0cdfc7e354fb28658de93fdd472c6_19)[5](#iffc0cdfc7e354fb28658de93fdd472c6_19)[and 202](#iffc0cdfc7e354fb28658de93fdd472c6_19)[4](#iffc0cdfc7e354fb28658de93fdd472c6_19)</u> | [3](#iffc0cdfc7e354fb28658de93fdd472c6_19) |
|  | <u>[Consolidated Balance Sheets at December 31, 202](#iffc0cdfc7e354fb28658de93fdd472c6_25)[5](#iffc0cdfc7e354fb28658de93fdd472c6_25)[and September 30, 20](#iffc0cdfc7e354fb28658de93fdd472c6_25)</u><u>[2](#iffc0cdfc7e354fb28658de93fdd472c6_25)5</u> | [4](#iffc0cdfc7e354fb28658de93fdd472c6_25) |
|  | <u>[Consolidated Statements of Cash Flows for the Three Months Ended December 31, 202](#iffc0cdfc7e354fb28658de93fdd472c6_31)[5](#iffc0cdfc7e354fb28658de93fdd472c6_31)[and 202](#iffc0cdfc7e354fb28658de93fdd472c6_31)[4](#iffc0cdfc7e354fb28658de93fdd472c6_31)</u> | [5](#iffc0cdfc7e354fb28658de93fdd472c6_31) |
|  | <u>[Consolidated Statements of Shareholders' Equity for the Three Months Ended December 31, 202](#iffc0cdfc7e354fb28658de93fdd472c6_34)[5](#iffc0cdfc7e354fb28658de93fdd472c6_34)[and 202](#iffc0cdfc7e354fb28658de93fdd472c6_34)[4](#iffc0cdfc7e354fb28658de93fdd472c6_34)</u> | [6](#iffc0cdfc7e354fb28658de93fdd472c6_34) |
|  | <u>[Condensed Notes to Consolidated Financial Statements](#iffc0cdfc7e354fb28658de93fdd472c6_40)</u> | [7](#iffc0cdfc7e354fb28658de93fdd472c6_40) |
| **<u>[Item 2.](#iffc0cdfc7e354fb28658de93fdd472c6_121)</u>** | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#iffc0cdfc7e354fb28658de93fdd472c6_121)</u> | [18](#iffc0cdfc7e354fb28658de93fdd472c6_121) |
| **<u>[Item 3.](#iffc0cdfc7e354fb28658de93fdd472c6_175)</u>** | <u>[Quantitative and Qualitative Disclosures About Market Risk](#iffc0cdfc7e354fb28658de93fdd472c6_175)</u> | [27](#iffc0cdfc7e354fb28658de93fdd472c6_175) |
| **<u>[Item 4.](#iffc0cdfc7e354fb28658de93fdd472c6_178)</u>** | <u>[Controls and Procedures](#iffc0cdfc7e354fb28658de93fdd472c6_178)</u> | [27](#iffc0cdfc7e354fb28658de93fdd472c6_178) |
|  | **<u>[PART II — OTHER INFORMATION](#iffc0cdfc7e354fb28658de93fdd472c6_181)</u>** |  |
| **<u>[Item 1.](#iffc0cdfc7e354fb28658de93fdd472c6_184)</u>** | <u>[Legal Proceedings](#iffc0cdfc7e354fb28658de93fdd472c6_184)</u> | [28](#iffc0cdfc7e354fb28658de93fdd472c6_184) |
| **<u>[Item 1A.](#iffc0cdfc7e354fb28658de93fdd472c6_187)</u>** | <u>[Risk Factors](#iffc0cdfc7e354fb28658de93fdd472c6_187)</u> | [28](#iffc0cdfc7e354fb28658de93fdd472c6_187) |
| **<u>[Item 5.](#iffc0cdfc7e354fb28658de93fdd472c6_196)</u>** | <u>[Other Information](#iffc0cdfc7e354fb28658de93fdd472c6_196)</u> | [28](#iffc0cdfc7e354fb28658de93fdd472c6_196) |
| **<u>[Item 6.](#iffc0cdfc7e354fb28658de93fdd472c6_199)</u>** | <u>[Exhibits](#iffc0cdfc7e354fb28658de93fdd472c6_199)</u> | [28](#iffc0cdfc7e354fb28658de93fdd472c6_199) |
| **<u>[SIGNATURES](#iffc0cdfc7e354fb28658de93fdd472c6_202)</u>** | **<u>[SIGNATURES](#iffc0cdfc7e354fb28658de93fdd472c6_202)</u>** |  |

---

------

<u>[**Table of Contents**](#iffc0cdfc7e354fb28658de93fdd472c6_7)</u>

**PART I** — **FINANCIAL INFORMATION**

**Item 1.**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **FINANCIAL STATEMENTS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Hillenbrand, Inc.**

**Consolidated Statements of Operations (Unaudited)**

(*in millions, except per share data*)

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| Net revenue | $550.2 | $706.9 |
| Cost of goods sold | 366.5 | 471.9 |
| &nbsp;&nbsp;&nbsp;Gross profit | 183.7 | 235.0 |
| Selling, general, and administrative expenses | 149.2 | 171.1 |
| Amortization expense | 22.8 | 25.2 |
| Loss on divestiture | 3.4 |  |
| Pension settlement gain |  | (1.7) |
| Interest expense, net | 20.2 | 25.1 |
| &nbsp;&nbsp;&nbsp;(Loss) income before income taxes | (11.9) | 15.3 |
| Income tax (benefit) expense | (12.9) | 6.4 |
| &nbsp;&nbsp;&nbsp;Consolidated net income | 1.0 | 8.9 |
| Less: Net income attributable to noncontrolling interests | 3.2 | 2.5 |
| &nbsp;&nbsp;&nbsp;Net (loss) income attributable to Hillenbrand | $(2.2) | $6.4 |
| (Loss) earnings per share |  |  |
| Basic (loss) earnings per share | $(0.03) | $0.09 |
| Diluted (loss) earnings per share | $(0.03) | $0.09 |
| Weighted average shares outstanding (basic) | 70.9 | 70.6 |
| Weighted average shares outstanding (diluted) | 70.9 | 70.6 |

---

*See Condensed Notes to Consolidated Financial Statements*

------

<u>[**Table of Contents**](#iffc0cdfc7e354fb28658de93fdd472c6_7)</u>

**Hillenbrand, Inc.**

**Consolidated Statements of Comprehensive Income (Loss) (Unaudited)**

*(in millions)*

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| Consolidated net income | $1.0 | $8.9 |
| Changes in other comprehensive income (loss), net of tax: |  |  |
| &nbsp;&nbsp;Currency translation adjustment <sup>(1)</sup> | 10.5 | (63.9) |
| &nbsp;&nbsp;&nbsp;Pension and postretirement | 0.1 | 0.8 |
| &nbsp;&nbsp;&nbsp;Change in net unrealized (loss) gain on derivative instruments | (0.6) | 27.9 |
| Total changes in other comprehensive income (loss), net of tax | 10.0 | (35.2) |
| Consolidated comprehensive income (loss) | 11.0 | (26.3) |
| &nbsp;&nbsp;&nbsp;Less: Comprehensive income attributable to noncontrolling interests | 2.9 | 1.9 |
| Comprehensive income (loss) attributable to Hillenbrand | $8.1 | $(28.2) |

---

<sup>(1)</sup> Includes gains and losses on intra-entity foreign currency transactions that are of a long-term investment nature.

*See Condensed Notes to Consolidated Financial Statements*

------

<u>[**Table of Contents**](#iffc0cdfc7e354fb28658de93fdd472c6_7)</u>

**Hillenbrand, Inc.**

**Consolidated Balance Sheets**

(*in millions*)

---

| | | |
|:---|:---|:---|
| | **December 31, 2025 (unaudited)** | **September 30,<br>2025** |
| **ASSETS** | | |
| **Current Assets** | | |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $173.1 | $164.8 |
| &nbsp;&nbsp;&nbsp;Trade receivables, net | 280.7 | 297.3 |
| &nbsp;&nbsp;&nbsp;Receivables from long-term manufacturing contracts, net | 274.7 | 278.8 |
| &nbsp;&nbsp;&nbsp;Inventories, net | 349.4 | 344.0 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 154.3 | 156.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 1232.2 | 1241.5 |
| Property, plant, and equipment, net | 233.9 | 238.5 |
| Operating lease right-of-use assets, net | 107.8 | 104.1 |
| Intangible assets, net | 1116.9 | 1136.0 |
| Goodwill | 1607.5 | 1601.4 |
| Equity method investments | 62.7 | 69.2 |
| Other long-term assets | 108.1 | 76.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Assets** | $4469.1 | $4467.1 |
| **LIABILITIES** |  |  |
| **Current Liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;Trade accounts payable | $342.5 | $364.4 |
| &nbsp;&nbsp;&nbsp;Liabilities from long-term manufacturing contracts and advances | 238.9 | 241.9 |
| &nbsp;&nbsp;&nbsp;Current portion of long-term debt | 22.9 | 22.8 |
| &nbsp;&nbsp;&nbsp;Accrued compensation | 83.2 | 109.0 |
| &nbsp;&nbsp;&nbsp;Other current liabilities | 279.0 | 282.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 966.5 | 1020.7 |
| Long-term debt | 1556.1 | 1502.0 |
| Accrued pension and postretirement healthcare | 81.7 | 82.5 |
| Operating lease liabilities | 80.4 | 77.1 |
| Deferred income taxes | 196.6 | 190.0 |
| Other long-term liabilities | 167.6 | 170.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Liabilities** | $3048.9 | $3042.9 |
| Commitments and contingencies (Note 13) |  |  |
| **SHAREHOLDERS' EQUITY** |  |  |
| Common stock, no par value (75.8 and 75.8 shares issued, 70.7 and 70.2 shares outstanding) |  |  |
| Additional paid-in capital | 713.5 | 717.9 |
| Retained earnings | 1005.4 | 1024.0 |
| Treasury stock (5.1 and 5.3 shares, at cost) | (220.0) | (227.1) |
| Accumulated other comprehensive loss | (117.8) | (128.1) |
| &nbsp;&nbsp;Hillenbrand Shareholders' Equity | 1381.1 | 1386.7 |
| Noncontrolling interests | 39.1 | 37.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Shareholders' Equity** | 1420.2 | 1424.2 |
| **Total Liabilities and Shareholders' Equity** | $4469.1 | $4467.1 |

---

*See Condensed Notes to Consolidated Financial Statements*

------

<u>[**Table of Contents**](#iffc0cdfc7e354fb28658de93fdd472c6_7)</u>

**Hillenbrand, Inc.**

**Consolidated Statements of Cash Flows (Unaudited)**

(*in millions*)

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| **Operating activities** |  |  |
| Consolidated net income | $1 | $8.9 |
| Adjustments to reconcile consolidated net income to cash provided by (used in) operating activities: |  |  |
| &nbsp;&nbsp;Depreciation and amortization | 33.0 | 37.9 |
| &nbsp;&nbsp;Deferred income taxes | (27.8) | (4.8) |
| &nbsp;&nbsp;Amortization of deferred financing costs | 1.0 | 1.2 |
| &nbsp;&nbsp;Share-based compensation | 4.7 | 4.7 |
| &nbsp;&nbsp;Trade accounts receivable, net and receivables from long-term manufacturing contracts | 20.1 | 17.2 |
| &nbsp;&nbsp;Inventories, net | (4.0) | (13.3) |
| &nbsp;&nbsp;Prepaid expenses and other current assets | 0.3 | (3.6) |
| &nbsp;&nbsp;Trade accounts payable | (22.8) | (23.8) |
| &nbsp;&nbsp;Liabilities from long-term manufacturing contracts and advances, |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; accrued compensation, and other current liabilities | (37.0) | (25.8) |
| &nbsp;&nbsp;Income taxes payable | 5.8 | (8.9) |
| &nbsp;&nbsp;Accrued pension and postretirement | (0.3) | (0.5) |
| &nbsp;&nbsp;Other, net | (1.4) | (0.5) |
| &nbsp;&nbsp; Net cash used in operating activities | (27.4) | (11.3) |
| **Investing activities** |  |  |
| &nbsp;&nbsp;&nbsp;Capital expenditures | (4.2) | (10.2) |
| &nbsp;&nbsp;&nbsp;Proceeds from sales of property, plant, and equipment | 3.2 | 0.5 |
| &nbsp;&nbsp;&nbsp;Cross-currency swap settlement |  | 9.1 |
| &nbsp;&nbsp;&nbsp;Collection of deferred purchase price receivables | 2.4 | 10.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by investing activities | 1.4 | 9.5 |
| **Financing activities** |  |  |
| &nbsp;&nbsp;&nbsp;Repayments on long-term debt | (5.7) | (4.9) |
| &nbsp;&nbsp;&nbsp;Proceeds from revolving credit facilities | 122.2 | 119.6 |
| &nbsp;&nbsp;&nbsp;Repayments on revolving credit facilities | (65.5) | (68.2) |
| &nbsp;&nbsp;&nbsp;Payments of dividends on common stock | (16.1) | (15.8) |
| &nbsp;&nbsp;&nbsp;Proceeds from stock option exercises | 0.7 | 0.8 |
| &nbsp;&nbsp;&nbsp;Payments for employee taxes on net settlement equity awards | (3.0) | (3.2) |
| &nbsp;&nbsp;&nbsp;Other, net | (1.4) | (1.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities | 31.2 | 26.8 |
| Effect of exchange rates on cash and cash equivalents | 1.7 | (14.4) |
| **Net cash flows** | 6.9 | 10.6 |
| **Cash, cash equivalents, and restricted cash:** |  |  |
| &nbsp;&nbsp;&nbsp;At beginning of period | 191.4 | 227.9 |
| &nbsp;&nbsp;&nbsp;At end of period | $198.3 | $238.5 |

---

*See Condensed Notes to Consolidated Financial Statements*

------

<u>[**Table of Contents**](#iffc0cdfc7e354fb28658de93fdd472c6_7)</u>

**Hillenbrand, Inc.**

**Consolidated Statements of Shareholders' Equity (Unaudited)**

*(in millions)*

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** |
| | **Common Stock** | **Additional<br>Paid-in<br>Capital** | **Retained<br>Earnings** | **Treasury Stock** | **Treasury Stock** | **Accumulated<br>Other<br>Comprehensive<br>Loss** | **Noncontrolling<br>Interests** | **Total** |
| | **Shares** | **Additional<br>Paid-in<br>Capital** | **Retained<br>Earnings** | **Shares** | **Amount** | **Accumulated<br>Other<br>Comprehensive<br>Loss** | **Noncontrolling<br>Interests** | **Total** |
| **Balance at September 30, 2025** | **75.8** | $**717.9** | $**1024.0** | **5.3** | $**(227.1)** | $**(128.1)** | $**37.5** | $**1424.2** |
| &nbsp;&nbsp;&nbsp;Total other comprehensive loss, net of tax |  |  |  |  |  | 10.3 | (0.3) | 10.0 |
| &nbsp;&nbsp;&nbsp;Net (loss) income |  |  | (2.2) |  |  |  | 3.2 | 1.0 |
| &nbsp;&nbsp;&nbsp;Issuance/retirement of stock for stock awards/options |  | (9.4) |  | (0.2) | 7.1 |  |  | (2.3) |
| &nbsp;&nbsp;&nbsp;Share-based compensation |  | 4.7 |  |  |  |  |  | 4.7 |
| &nbsp;&nbsp;Dividends ($0.2275 per share) |  | 0.3 | (16.4) |  |  |  | (1.3) | (17.4) |
| **Balance at December 31, 2025** | **75.8** | $**713.5** | $**1005.4** | **5.1** | $**(220.0)** | $**(117.8)** | $**39.1** | $**1420.2** |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** |
| | **Common Stock** | **Additional<br>Paid-in<br>Capital** | **Retained<br>Earnings** | **Treasury Stock** | **Treasury Stock** | **Accumulated<br>Other<br>Comprehensive<br>Loss** | **Noncontrolling<br>Interests** | **Total** |
| | **Shares** | **Additional<br>Paid-in<br>Capital** | **Retained<br>Earnings** | **Shares** | **Amount** | **Accumulated<br>Other<br>Comprehensive<br>Loss** | **Noncontrolling<br>Interests** | **Total** |
| **Balance at September 30, 2024** | **75.8** | $**712.6** | $**1045.2** | **5.6** | $**(238.2)** | $**(96.6)** | $**34.4** | $**1457.4** |
| &nbsp;&nbsp;&nbsp;Total other comprehensive income, net of tax |  |  |  |  |  | (34.6) | (0.6) | (35.2) |
| &nbsp;&nbsp;&nbsp;Net income |  |  | 6.4 |  |  |  | 2.5 | 8.9 |
| &nbsp;&nbsp;&nbsp;Issuance/retirement of stock for stock awards/options |  | (10.0) |  | (0.2) | 7.6 |  |  | (2.4) |
| &nbsp;&nbsp;&nbsp;Share-based compensation |  | 4.7 |  |  |  |  |  | 4.7 |
| &nbsp;&nbsp;Dividends ($0.225 per share) |  | 0.3 | (16.1) |  |  |  | (1.2) | (17.0) |
| **Balance at December 31, 2024** | **75.8** | $**707.6** | $**1035.5** | **5.4** | $**(230.6)** | $**(131.2)** | $**35.1** | $**1416.4** |

---

*See Condensed Notes to Consolidated Financial Statements*

------

<u>[**Table of Contents**](#iffc0cdfc7e354fb28658de93fdd472c6_7)</u>

**Hillenbrand, Inc.**

**Condensed Notes to Consolidated Financial Statements (Unaudited)**

(*in millions, except share and per share data****)***

1. <u>Background and Basis of Presentation</u>

Hillenbrand, Inc. (the "Company" or "Hillenbrand") is a global industrial company that provides highly-engineered processing equipment and solutions to customers around the world. Our portfolio is composed of leading industrial brands that serve large, attractive end markets, including durable plastics, food, and recycling. Guided by our Purpose, Shape What Matters for Tomorrow<sup>TM</sup>, we pursue excellence, collaboration, and innovation to shape solutions that best serve our people, our customers, and our communities. Customers choose Hillenbrand due to our reputation for designing, manufacturing, and servicing highly-engineered, mission-critical equipment and solutions that meet their unique and complex processing requirements.

Hillenbrand is composed of two reportable operating segments: Advanced Process Solutions and Molding Technology Solutions. Advanced Process Solutions is a leading global provider of highly-engineered process and material handling equipment, systems, and aftermarket parts and services for a variety of industries, including durable plastics, food, and recycling. Molding Technology Solutions is a global leader in highly-engineered equipment, systems, and aftermarket parts and service for the plastic technology processing industry. Molding Technology Solutions has a comprehensive product portfolio that includes injection molding and extrusion equipment, hot runner systems, process control systems, mold bases and components, and maintenance, repair, and operating ("MRO") supplies.

The Consolidated Financial Statements include the accounts of Hillenbrand and its subsidiaries. They also include three subsidiaries where the Company's ownership percentage is less than 100%. The Company's fiscal year ends on September 30. Unless otherwise stated, references to years refer to fiscal years.

These unaudited Consolidated Financial Statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial statements and therefore do not include all information required in accordance with United States ("U.S.") generally accepted accounting principles ("GAAP"). The unaudited Consolidated Financial Statements have been prepared on the same basis as, and should be read in conjunction with, the audited Consolidated Financial Statements and notes thereto included in the Company's latest Annual Report on Form 10-K for the year ended September 30, 2025, as filed with the SEC on November 19, 2025. In the opinion of management, these unaudited Consolidated Financial Statements reflect all adjustments necessary to present a fair statement of the Company's consolidated financial position and the consolidated results of operations and cash flows as of the dates and for the periods presented and are normal and recurring in nature. The interim period results are subject to variation and are not necessarily indicative of the consolidated results of operations to be expected for the full fiscal year.

The preparation of the Consolidated Financial Statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of net revenue and expenses during the period. Actual results could differ from those estimates. Examples of such estimates include, but are not limited to, revenue recognition under

the over time method, establishment of reserves related to credit losses, warranties, income taxes, litigation, and self-insurance.

***Acquisition by Lone Star***

As announced on October 15, 2025, on October 14, 2025, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement") with LSF12 Helix Parent, LLC, a Delaware limited liability company ("Parent"), and LSF12 Helix Merger Sub, Inc., an Indiana corporation and a wholly owned subsidiary of Parent ("Merger Sub"), providing for the merger of Merger Sub with and into Hillenbrand (the "Merger"), with Hillenbrand surviving the Merger as a wholly owned subsidiary of Parent. Parent and Merger Sub are affiliates of Lone Star Funds XII, L.P.

At the effective time of the Merger, on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Company's common stock issued and outstanding immediately prior to such time, other than shares of the Company's common stock owned by Hillenbrand, any wholly owned subsidiary of Hillenbrand, Parent, Merger Sub or any other wholly owned subsidiary of Parent (each of which will be cancelled), will be converted into the right to receive $32.00 in cash, without interest.

The transactions contemplated by the Merger Agreement were unanimously approved by Hillenbrand's Board of Directors, and Hillenbrand's shareholders voted to approve the Merger Agreement at a special meeting of the Company's shareholders on

------

<u>[**Table of Contents**](#iffc0cdfc7e354fb28658de93fdd472c6_7)</u>

January 8, 2026. The Merger is expected to close by the end of the first quarter of calendar year 2026, subject to customary closing conditions.

2.<u>Summary of Significant Accounting Policies</u>

The significant accounting policies used in preparing the Consolidated Financial Statements are consistent with the accounting policies described in the Company's Annual Report on Form 10-K as of and for the year ended September 30, 2025.

***Recently issued accounting standards***

In December 2023, the FASB issued ASU 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*, which expands disclosures in an entity's income tax rate reconciliation table and regarding cash taxes paid both in the U.S. and foreign jurisdictions. ASU 2023-09 will be effective for annual periods beginning after December 15, 2024 (fiscal 2026). The Company is currently evaluating the impact of ASU 2023-09 on the Consolidated Financial Statements.

In November 2024, the FASB issued ASU 2024-03, *Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses* (ASU 2024-03), which requires, among other items, additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the face of the Consolidated Statement of Operations. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026 (fiscal 2028), and for interim periods within fiscal years beginning after December 15, 2027 (fiscal 2029), with early adoption permitted. The Company is currently evaluating the impact of ASU 2024-03 on the Consolidated Financial Statements.

No other new accounting pronouncements recently adopted or issued had or are expected to have a material impact on the Consolidated Financial Statements.

3.<u>Revenue Recognition</u>

Net revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services and is recognized when performance obligations are satisfied under the terms of contracts with customers.

***Contract balances***

The balance in receivables from long-term manufacturing contracts at December 31, 2025 and September 30, 2025, was $274.7 and $278.8, respectively. The change was driven by the impact of net revenue recognized prior to billings to customers. The balance in the liabilities from long-term manufacturing contracts and advances at December 31, 2025 and September 30, 2025, was $238.9 and $241.9, respectively, and consists primarily of cash payments received or due in advance of satisfying performance obligations. The net revenue recognized for the three months ended December 31, 2025 and 2024, related to liabilities from long-term manufacturing contracts and advances as of September 30, 2025 and 2024, was $76.0 and $95.6, respectively. During the three months ended December 31, 2025 and 2024, the adjustments related to performance obligations satisfied in previous periods were immaterial.

***Transaction price allocated to the remaining performance obligations***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

As of December 31, 2025, the aggregate amount of transaction price of remaining performance obligations for the Company, which corresponds to backlog as defined in Part I, Item 2 of this Quarterly Report on Form 10-Q, was $1,486.7. Approximately 74% of these performance obligations are expected to be satisfied over the next twelve months, and the remaining performance obligations, primarily within one to three years.

------

<u>[**Table of Contents**](#iffc0cdfc7e354fb28658de93fdd472c6_7)</u>

***Disaggregation of revenue***

The following tables present net revenue by geography:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** |
| | **Advanced Process Solutions** | **Molding Technology Solutions** | **Total** | **Advanced Process Solutions** | **Molding Technology Solutions** | **Total** |
| **Geography** <sup>(1)</sup> | | | | | | |
| &nbsp;&nbsp;Americas | $198.5 | $29.0 | $227.5 | $229.2 | $102.9 | $332.1 |
| &nbsp;&nbsp;Asia | 128.4 | 31.6 | 160.0 | 128.8 | 60.2 | 189.0 |
| &nbsp;&nbsp;Europe, the Middle East, and Africa | 136.7 | 26.0 | 162.7 | 153.1 | 32.7 | 185.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $463.6 | $86.6 | $550.2 | $511.1 | $195.8 | $706.9 |

---

<sup>(1)</sup> The Company attributes net revenue to a geography based upon the location of the end customer.

The following tables present net revenue by timing of transfer:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** |
| | **Advanced Process Solutions** | **Molding Technology Solutions** | **Total** | **Advanced Process Solutions** | **Molding Technology Solutions** | **Total** |
| **Timing of transfer** | | | | | | |
| &nbsp;&nbsp;Point in time | $256.5 | $85.7 | $342.2 | $269.8 | $181.1 | $450.9 |
| &nbsp;&nbsp;Over time | 207.1 | 0.9 | 208.0 | 241.3 | 14.7 | 256.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $463.6 | $86.6 | $550.2 | $511.1 | $195.8 | $706.9 |

---

------

4.<u>Supplemental Consolidated Balance Sheet Information</u>

---

| | | |
|:---|:---|:---|
| | **December 31, 2025** | **September 30, 2025** |
| Allowance for credit losses | $11.8 | $11.3 |
| Warranty reserves | $43.1 | $46.0 |
| Accumulated depreciation on property, plant, and equipment | $251.8 | $245.0 |
| Inventories, net: |  |  |
| &nbsp;&nbsp;&nbsp;Raw materials and components | $165.8 | $164.7 |
| &nbsp;&nbsp;&nbsp;Work in process | 86.4 | 81.9 |
| &nbsp;&nbsp;&nbsp;Finished goods | 97.2 | 97.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total inventories, net | $349.4 | $344.0 |

---

The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same amounts shown in the Consolidated Statements of Cash Flows:

---

| | | |
|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2024** |
| Cash and cash equivalents | $173.1 | $208.0 |
| Short-term restricted cash included in other current assets | 6.5 | 6.9 |
| Long-term restricted cash included in other long-term assets | 18.7 | 23.6 |
| Total cash and cash equivalents and restricted cash shown in the Consolidated Statements of Cash Flows | $198.3 | $238.5 |

---

*Equity Method Investment*

The Consolidated Financial Statements include our 48.74% interest in Milacron Holdings, which is accounted for using the equity method of accounting as we have significant influence over the operating and financial policies but not controlling interests. When we record our proportionate share of net income, we record it as a reduction or increase to selling, general and administrative expenses in the Consolidated Statements of Operations and adjust the carrying value of our equity method investment. The value of our equity method investments, which is recorded in Equity method investments in the Consolidated Balance Sheet, was $62.6 and $68.8 at December 31, 2025 and September 30, 2025, respectively. We recorded our proportionate share of net (loss) income from equity method investments of $(6.2) and $2.8 for the three months ended December 31, 2025 and 2024, respectively, as a component of selling, general and administrative expenses.

*Supplier Finance Program*

The Company has an agreement with a third-party to facilitate a supply chain finance ("SCF") program with participating financial institutions. The SCF program allows qualifying suppliers to sell their receivables, on an invoice level at the selection of the supplier, from the Company to the financial institutions and negotiate their outstanding receivable arrangements and associated fees directly with the financial institutions. Hillenbrand is not party to the agreements between the supplier and the financial institutions. The supplier invoices that have been confirmed as valid under the SCF program require payment in full by the financial institutions to the supplier by the original maturity date of the invoice, or discounted payment at an earlier date as agreed upon with the supplier. The Company's obligations to its suppliers, including amounts due and scheduled payment terms, are not impacted by a supplier's participation in the SCF program.

All outstanding amounts related to suppliers participating in the SCF program are recorded upon confirmation with the third-party financial institutions in trade accounts payable in the Consolidated Balance Sheets, and associated payments are included

------

in cash used in operating activities in the Consolidated Statements of Cash Flows. The Company's outstanding obligations included in trade accounts payable as of December 31, 2025 and September 30, 2025, were $12.5 and $13.7, respectively.

*Trade Receivables Financing Agreements*

The Company sells a small percentage of its trade receivables to outside financial institutions in the normal course of business. These trade receivable financing agreements are accounted for as a true sale of assets under the provisions of Accounting Standards Codification ("ASC") 860, *Transfer and Servicing* ("ASC 860"). For one of the Company's trade receivable financing agreement with a financial institution (the "Agreement"), we receive the majority of the proceeds of the trade receivables sold to the financial institution upon sale in cash (level 1 fair value measurement) with the remaining portion of the proceeds held by the financial institution as a deferred purchase price ("DPP") (level 2 fair value measurement) until the collection of the trade receivables sold. The DPP receivables are ultimately realized by the Company following the collection of the underlying trade receivables sold to the financial institution (typically within 90 - 120 days). As defined in the Agreement, the financial institution is responsible for any credit risk associated with the sold trade receivables. There is no limit on the amount of trade receivables that can be sold under the Agreement; however, all trade receivables must be accepted by the financial institution prior to sale.

Sales of trade receivables under the Agreement and other trade receivable factoring arrangements were $76.7 and $70.8 for the three months ended December 31, 2025 and 2024, respectively, and cash collections from customers on trade receivables sold were $75.7 and $71.7 during the three months ended December 31, 2025 and 2024, respectively. The Company acts as a servicer (collects customer cash on behalf of the financial institution) for one of its trade receivables factoring arrangements. The servicing fee associated with this trade receivables factoring arrangement was not material to the Company for the three months ended December 31, 2025 or 2024, respectively. Amounts collected on behalf of the financial institution under this trade receivables factoring arrangement and owed to the financial institution were $0.6 and $4.2 at December 31, 2025 and September 30, 2025, respectively. The loss on the sale of trade receivables under the Agreement and other trade receivables factoring arrangements was not material to the Company for the three months ended December 31, 2025 or 2024. As of December 31, 2025 and September 30, 2025, trade receivables in the amount of $26.5 and $28.3, respectively were sold to the financial institution and are not reflected in trade receivables in the Consolidated Balance Sheets.

The following roll forward summarizes the activity related to the DPP receivables:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2024** |
| Beginning DPP receivables balance | $3.7 | $6.7 |
| Non-cash additions to DPP receivables | 3.4 | 9.2 |
| Cash collections on DPP receivables | (2.4) | (10.1) |
| &nbsp;&nbsp;Ending DPP receivables balance | $4.7 | $5.8 |

---

5.<u>Leases</u>

For the three months ended December 31, 2025 and 2024, the Company recognized $8.0 and $10.5 of operating lease expense, respectively, including short-term lease expense and variable lease costs, which were immaterial in each period. The Company's finance leases were insignificant as of December 31, 2025 and September 30, 2025.

The following table presents supplemental Consolidated Balance Sheet information related to the Company's operating leases:

------

---

| | | |
|:---|:---|:---|
| | **December 31, 2025** | **September 30, 2025** |
| Operating lease right-of-use assets, net | $107.8 | $104.1 |
| Other current liabilities | 20.0 | 19.6 |
| Operating lease liabilities | 80.4 | 77.1 |
| Total operating lease liabilities | $100.4 | $96.7 |
| Weighted-average remaining lease term (in years) | 5.6 | 5.6 |
| Weighted-average discount rate | 4.5% | 4.3% |

---

As of December 31, 2025, the maturities of the Company's operating lease liabilities were as follows:

---

| | |
|:---|:---|
| 2026 (excluding the three months ended December 31, 2025) | $19.0 |
| 2027 | 22.1 |
| 2028 | 19.3 |
| 2029 | 17.0 |
| 2030 | 15.5 |
| Thereafter | 21.2 |
| Total lease payments | 114.1 |
| Less: imputed interest | (13.7) |
| Total present value of lease payments | $100.4 |

---

Supplemental Consolidated Statements of Cash Flow information related to the Company's operating leases is as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** |
| | **2025** | **2024** |
| Cash paid for amounts included in the measurement of operating lease liabilities | $6.7 | $8.0 |
| Operating lease right-of-use assets, net obtained in exchange for new operating lease liabilities | 6.1 | 4.6 |

---

6.<u>Intangible Assets and Goodwill</u>

***Intangible Assets***

Intangible assets are stated at the lower of cost or fair value. Intangible assets are amortized on a straight-line basis over periods ranging from three to 21 years, representing the period over which the Company expects to receive future economic benefits from these assets. The Company assesses the carrying value of indefinite-lived trade names annually, or more often if events or changes in circumstances indicate there may be an impairment.

------

The following table summarizes the carrying amounts and related accumulated amortization for intangible assets as of:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **September 30, 2025** | **September 30, 2025** |
| | **Cost** | **Accumulated<br>Amortization** | **Cost** | **Accumulated<br>Amortization** |
| Finite-lived assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Customer relationships | $1245.7 | $(439.3) | $1239.7 | $(419.1) |
| &nbsp;&nbsp;&nbsp;Technology, including patents | 189.3 | (116.7) | 189.0 | (113.4) |
| &nbsp;&nbsp;&nbsp;Software | 67.5 | (40.9) | 66.5 | (39.2) |
| &nbsp;&nbsp;&nbsp;Trade names | 54.0 | (18.2) | 53.9 | (16.7) |
|  | 1556.5 | (615.1) | 1549.1 | (588.4) |
| Indefinite-lived assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Trade names | 175.5 |  | 175.3 |  |
| &nbsp;&nbsp;&nbsp;Total | $1732.0 | $(615.1) | $1724.4 | $(588.4) |

---

Finite-lived intangible assets, net of $623.3 and $638.1 are included in the Advanced Process Solutions reportable operating segment at December 31, 2025 and September 30, 2025, respectively. Indefinite-lived intangible assets of $115.0 and $114.8 are included in the Advanced Process Solutions reportable operating segment at December 31, 2025 and September 30, 2025, respectively. The net change in intangible assets in the Advanced Process Solutions reportable operating segment during the three months ended December 31, 2025, was driven primarily by amortization and foreign currency adjustments.

Finite-lived intangible assets, net of $302.3 and $306.2 are included in the Molding Technology Solutions reportable operating segment at December 31, 2025 and September 30, 2025, respectively. Indefinite-lived intangible assets of $60.5 are included in the Molding Technology Solutions reportable operating segment at both December 31, 2025 and September 30, 2025. The net change in intangible assets in the Molding Technology Solutions reportable operating segment during the three months ended December 31, 2025, was driven primarily by amortization and foreign currency adjustments.

***Goodwill***

Goodwill is not amortized, but is subject to annual impairment tests. Goodwill has been assigned to reporting units within the reportable operating segments. The Company assesses the carrying value of goodwill annually, or more often if events or changes in circumstances indicate there may be impairment. Impairment testing is performed at a reporting unit level.

The following table summarizes the changes in the Company's goodwill, by reportable operating segment, for the three months ended December 31, 2025:

---

| | | | |
|:---|:---|:---|:---|
| | **Advanced Process Solutions** | **Molding Technology Solutions** | **Total** |
| Balance as of September 30, 2025 | $1458.8 | $142.6 | $1601.4 |
| &nbsp;&nbsp;&nbsp;Foreign currency adjustments | 4.6 | 1.5 | 6.1 |
| Balance as of December 31, 2025  | $1463.4 | $144.1 | $1607.5 |

---

During the three months ended December 31, 2025 and 2024, the Company did not observe any triggering events or substantive changes in circumstances requiring the need for an interim impairment assessment.

------

7.<u>Financing Agreements</u>

The following table summarizes Hillenbrand's current and long-term debt as of:

---

| | | |
|:---|:---|:---|
| | **December 31, 2025** | **September 30, 2025** |
| $1,000 revolving credit facility (excluding outstanding letters of credit) | $283.5 | $225.0 |
| €240 term loan | 278.7 | 281.3 |
| $175 term loan | 172.8 | 175.0 |
| $500 senior unsecured notes <sup>(1)</sup> | 496.2 | 495.8 |
| $350 senior unsecured notes <sup>(2)</sup> | 347.8 | 347.7 |
| &nbsp;&nbsp;&nbsp;Total debt | 1579.0 | 1524.8 |
| Less: current portion | 22.9 | 22.8 |
| &nbsp;&nbsp;&nbsp;Total long-term debt | $1556.1 | $1502.0 |

---

<sup>(1)</sup> Includes unamortized debt issuance costs of $3.8 and $4.2 at December 31, 2025 and September 30, 2025, respectively.

<sup>(2)</sup> Includes unamortized debt issuance costs of $2.2 and $2.3 at December 31, 2025 and September 30, 2025, respectively.

On July 9, 2025, the Company entered into a Fifth Amended and Restated Credit Agreement (the "Amended Credit Agreement"), which governs the multi-currency revolving credit facility (the "Facility"), by and among Hillenbrand and certain of its affiliates, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent. The Amended Credit Agreement decreased the maximum principal amount available for borrowing under the Facility to $700.0. The Amended Credit Agreement extended the maturity date of the Facility to July 9, 2030. The Amended Credit Agreement further provided for a U.S. Dollar denominated $175.0 term loan facility (the "$175 Term Loan") and a delayed-draw term loan facility in an aggregate principal amount of up to €240.0 (the "€240 Term Loan"). As of December 31, 2025, the Company had $15.8 in outstanding letters of credit issued and $400.7 of borrowing capacity under the Facility, of which $34.5 was available as of such date based on the Company's most restrictive covenant. The weighted-average interest rate on borrowings under the Facility was 3.52% and 4.96% for the three months ended December 31, 2025 and 2024, respectively. The weighted average facility fee on the Facility was 0.24% and 0.24% for the three months ended December 31, 2025 and 2024, respectively. The weighted-average interest rate on the $175 term loan was 5.85% for the three months ended December 31, 2025. The weighted-average interest rate on the €240 term loan was 3.74% for the three months ended December 31, 2025.

Remaining unamortized deferred financing costs related to the Facility, $175 term loan and €240 term loan were $5.5 in aggregate, as of December 31, 2025, and are being amortized to interest expense over the remaining term of these agreements.

In the normal course of business, the Company provides, primarily to certain customers, bank guarantees and other credit arrangements in support of performance, warranty, advance payment, and other contractual obligations. This form of trade finance is customary in the industry and, as a result, the Company maintains adequate capacity to provide the guarantees. As of December 31, 2025 and September 30, 2025, the Company had credit arrangements totaling $668.0 and $666.1, respectively, under which $363.3 and $374.3, respectively, were used for guarantees. These arrangements include the Company's Syndicated L/G Facility Agreement ("L/G Facility") and other ancillary credit facilities. Remaining unamortized deferred financing costs related to the L/G Facility were $1.2 as of December 31, 2025, and are being amortized to interest expense over the remaining term of the agreement.

As of December 31, 2025, Hillenbrand was in compliance with all covenants contained in the foregoing agreements and credit instruments and there were no events of default.

------

8.<u>Retirement Benefits</u>

***Defined Benefit Plans***

Components of net periodic pension cost (benefit) included in the Consolidated Statements of Operations were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **U.S. Pension Benefits** | **U.S. Pension Benefits** | **Non-U.S. Pension Benefits** | **Non-U.S. Pension Benefits** |
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| Service costs | $— | $— | $0.8 | $0.7 |
| Interest costs | 0.2 | 0.2 | 0.7 | 0.8 |
| Expected return on plan assets |  |  | (0.3) | (0.3) |
| Amortization of net loss (gain) | 0.1 |  | 0.1 | (0.2) |
| Settlement gain |  | (1.7) |  |  |
| &nbsp;&nbsp;&nbsp;Net periodic pension cost (benefit) | $0.3 | $(1.5) | $1.3 | $1.0 |

---

On July 18, 2023, we announced an offer to provide former employees who are participants in the Company's U.S. defined benefit pension plan (the "Plan") the opportunity to elect a lump sum distribution of their earned Plan benefits. The Plan's fiduciaries made lump sum payments to electing eligible participants in December 2023, funded by the existing assets in the Plan. In April 2024, the remaining assets of the Plan were used to purchase annuities to support the remaining obligation, resulting in the termination and liquidation of the Plan. During the three months ended December 31, 2024, the Company received one-time premium refunds of $1.7 related to the termination of the Plan, which was recorded as a pretax pension settlement gain on the Consolidated Statement of Operations.

***Defined Contribution Plans***

Expenses related to the Company's defined contribution plans were $3.1 and $3.1 for the three months ended December 31, 2025, and 2024, respectively.

9.<u>Income Taxes</u>

The effective tax rates for the three months ended December 31, 2025 and 2024 were 108.4% and 41.8%, respectively. The increase in the effective tax rate was primarily driven by one-time discrete impacts related to the finalization of the income tax accounting related to the sale of Milacron and related restructuring activities and the effect of the approval of an incentive reduced income tax rate for certain operations located in China, partially offset by the geographic mix of earnings.

------

10.<u>Earnings per share</u>

The dilutive effects of performance-based stock awards were included in the computation of diluted earnings per share at the level the related performance criteria were met through the respective Consolidated Balance Sheet date. Potential dilutive effects, representing approximately 470,000 and 630,000 shares at December 31, 2025 and 2024, respectively, were excluded from the computation of diluted earnings per share as the related performance criteria were not yet met, although the Company expects to meet various levels of criteria in the future.

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| Net (loss) income attributable to Hillenbrand | $(2.2) | $6.4 |
| Weighted-average shares outstanding (basic - in millions) | 70.9 | 70.6 |
| Effect of dilutive stock options and other unvested equity awards (in millions) |  |  |
| Weighted-average shares outstanding (diluted - in millions) | 70.9 | 70.6 |
| Basic (loss) earnings per share | $(0.03) | $0.09 |
| Diluted (loss) earnings per share | $(0.03) | $0.09 |
| Shares with anti-dilutive effect excluded from the computation of diluted earnings per share (in millions) | 1.1 | 0.9 |

---

11. <u>Accumulated Other Comprehensive Loss</u>

The following tables summarize the changes in the accumulated balances for each component of accumulated other comprehensive loss:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Pension and<br>Postretirement** | **Currency**<br>**Translation** <sup>(1)</sup> | **Net<br>Unrealized<br>(Loss) Gain<br>on Derivative<br>Instruments** | **Total<br>Attributable<br>to<br>Hillenbrand,<br>Inc.** | **Noncontrolling<br>Interests** | **Total** |
| Balance at September 30, 2025 | $(13.8) | $(51.9) | $(62.4) | $(128.1) |  |  |
| &nbsp;&nbsp;&nbsp;Other comprehensive income (loss) before reclassifications: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before tax amount | (0.1) | 10.8 | (0.7) | 10.0 | $(0.3) | $9.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax benefit |  |  | 0.2 | 0.2 |  | 0.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After tax amount | (0.1) | 10.8 | (0.5) | 10.2 | (0.3) | 9.9 |
| &nbsp;&nbsp;Amounts reclassified from accumulated other comprehensive loss <sup>(2)</sup> | 0.2 |  | (0.1) | 0.1 |  | 0.1 |
| Net current period other comprehensive income (loss) | 0.1 | 10.8 | (0.6) | 10.3 | $(0.3) | $10.0 |
| Balance at December 31, 2025 | $(13.7) | $(41.1) | $(63.0) | $(117.8) |  |  |

---

<sup>(1)</sup> Includes gain and losses on intra-entity foreign currency transactions that are of a long-term investment nature.

<sup>(2)</sup> Amounts are net of tax.

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Pension and<br>Postretirement** | **Currency**<br>**Translation** <sup>(1)</sup> | **Net<br>Unrealized<br>(Loss) Gain<br>on Derivative<br>Instruments** | **Total<br>Attributable<br>to<br>Hillenbrand,<br>Inc.** | **Noncontrolling<br>Interests** | **Total** |
| Balance at September 30, 2024 | $(15.6) | $(55.4) | $(25.6) | $(96.6) |  |  |
| &nbsp;&nbsp;&nbsp;Other comprehensive income (loss) before reclassifications: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before tax amount | 1.1 | (63.3) | 26.5 | (35.7) | $(0.6) | $(36.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax benefit (expense) | (0.3) |  | 0.7 | 0.4 |  | 0.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After tax amount | 0.8 | (63.3) | 27.2 | (35.3) | (0.6) | (35.9) |
| &nbsp;&nbsp;Amounts reclassified from accumulated other comprehensive loss <sup>(2)</sup> |  |  | 0.7 | 0.7 |  | 0.7 |
| Net current period other comprehensive income (loss) | 0.8 | (63.3) | 27.9 | (34.6) | $(0.6) | $(35.2) |
| Balance at December 31, 2024 | $(14.8) | $(118.7) | $2.3 | $(131.2) |  |  |

---

<sup>(1)</sup> Includes gains and losses on intra-foreign currency transactions that are of a long-term investment nature.

<sup>(2)</sup> Amounts are net of tax.

Reclassifications out of accumulated other comprehensive loss include:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** |
| | **Amortization of Pension and<br>Postretirement** <sup>(1)</sup> | **Amortization of Pension and<br>Postretirement** <sup>(1)</sup> | | |
| | **Net Loss<br>Recognized** | **Prior Service Costs<br>Recognized** | **(Gain) Loss on**<br>**Derivative<br>Instruments** |<br>**Total** |
| Affected Line in the Consolidated Statement of Operations: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net revenue | $— | $— | $(0.1) | $(0.1) |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative expenses | 0.2 |  |  | 0.2 |
| Total before tax | $0.2 | $— | $(0.1) | $0.1 |
| Tax expense |  |  |  | $— |
| Total reclassifications for the period, net of tax |  |  |  | $0.1 |

---

<sup>(1)</sup> These accumulated other comprehensive loss components are included in the computation of net periodic pension (benefit) cost (see Note 8).

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** |
| | **Amortization of Pension and<br>Postretirement** <sup>(1)</sup> | **Amortization of Pension and<br>Postretirement** <sup>(1)</sup> | | |
| | **Net Loss<br>Recognized** | **Prior Service Costs<br>Recognized** | **(Gain) Loss on**<br>**Derivative<br>Instruments** |<br>**Total** |
| Affected Line in the Consolidated Statement of Operations: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net revenue | $— | $— | $0.3 | $0.3 |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative expenses |  |  | 0.5 | 0.5 |
| Total before tax | $— | $— | $0.8 | $0.8 |
| Tax expense |  |  |  | (0.1) |
| Total reclassifications for the period, net of tax |  |  |  | $0.7 |

---

<sup>(1)</sup> These accumulated other comprehensive loss components are included in the computation of net periodic pension (benefit) cost (see Note 8).

------

12.<u>Share-Based Compensation</u> 

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| Share-based compensation costs | $4.7 | $4.7 |
| Less impact of income taxes | 1.1 | 1.1 |
| &nbsp;&nbsp;&nbsp;Share-based compensation costs, net of tax | $3.6 | $3.6 |

---

The Company has share-based compensation with long-term performance-based metrics that are contingent upon the Company's relative total shareholder return and the creation of shareholder value, as well as time-based awards. Relative total shareholder return is determined by comparing the Company's total shareholder return during a three-year period to the respective total shareholder returns of companies in a designated stock index. Creation of shareholder value is measured by the cumulative cash returns and final period net operating profit after tax compared to the established hurdle rate over a three-year period. For the performance-based awards contingent upon the creation of shareholder value, compensation expense is adjusted each quarter based upon actual results to date and any changes to forecasted information on each of the separate grants.

During the three months ended December 31, 2025, the Company made the following grants:

---

| | |
|:---|:---|
| | **Number of<br>Units** |
| Time-based stock awards | 642,170 |

---

The Company's time-based stock awards granted during the three months ended December 31, 2025, had weighted-average grant date fair values of $31.61. These units will be expensed on a straight-line basis over the vesting period.

13.<u>Commitments and Contingencies</u>

From time to time, Hillenbrand is involved in claims, lawsuits, and government proceedings relating to its operations, including environmental, antitrust, patent infringement, business practices, commercial transactions, product and general liability, workers' compensation, auto liability, employment-related, and other matters. The ultimate outcome of any claims, lawsuits, and proceedings cannot be predicted with certainty. An estimated loss from these contingencies is recognized when the Company believes it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated; however, it is difficult to measure the actual loss that might be incurred related to these matters. If a loss is not considered probable or cannot be reasonably estimated, the Company is required to make a disclosure if there is at least a reasonable possibility that a significant loss may have been incurred. Legal fees associated with claims and lawsuits are generally expensed as incurred.

Claims covered by insurance have in most instances deductibles and self-funded retentions up to $0.5 per occurrence or per claim, depending upon the type of coverage and policy period. For auto, workers' compensation, and general liability claims in the U.S., outside insurance companies and third-party claims administrators generally assist in establishing individual claim reserves. An independent outside actuary often provides estimates of ultimate projected losses, including incurred but not reported claims, which are used to establish reserves for losses. For all other types of claims, reserves are established when payment is considered probable and are based upon advice from internal and external counsel and historical settlement information for such claims.

The recorded amounts represent the best estimate of costs that the Company will incur in relation to such exposures, but it is possible that actual costs will differ from those estimates.

14.<u>Fair Value Measurements</u>

Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are from sources independent of the Company. Unobservable inputs reflect the Company's assumptions about the factors market participants would use in valuing the asset or liability, developed based upon the best information available in the circumstances. The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels:

------

---

| | |
|:---|:---|
| Level 1: | Inputs are quoted prices in active markets for identical assets or liabilities. |
| Level 2: | Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. |
| Level 3: | Inputs are unobservable for the asset or liability. |

---

See the section below titled "Valuation techniques" for further discussion of how Hillenbrand determines fair value for certain assets and liabilities.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Carrying Value at December 31, 2025** | **Fair Value at December 31, 2025**<br>**Using Inputs Considered as:** | **Fair Value at December 31, 2025**<br>**Using Inputs Considered as:** | **Fair Value at December 31, 2025**<br>**Using Inputs Considered as:** |
| | **Carrying Value at December 31, 2025** | **Level 1** | **Level 2** | **Level 3** |
| Assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $173.1 | $173.1 | $— | $— |
| &nbsp;&nbsp;&nbsp;DPP receivables | 4.7 |  | 4.7 |  |
| &nbsp;&nbsp;&nbsp;Restricted cash | 0.6 | 0.6 |  |  |
| &nbsp;&nbsp;&nbsp;Restricted cash for benefit plan contributions | 24.6 | 24.6 |  |  |
| &nbsp;&nbsp;&nbsp;Investments in rabbi trust | 6.9 | 6.9 |  |  |
| &nbsp;&nbsp;&nbsp;Derivative instruments | 12.4 |  | 12.4 |  |
| Liabilities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Revolving credit facility | 283.5 |  | 283.5 |  |
| &nbsp;&nbsp;$175 term loan | 172.8 |  | 172.8 |  |
| &nbsp;&nbsp;€240 term loan | 278.7 |  | 278.7 |  |
| &nbsp;&nbsp;$350 senior unsecured notes | 350.0 | 350.6 |  |  |
| &nbsp;&nbsp;$500 senior unsecured notes | 500.0 | 512.2 |  |  |
| &nbsp;&nbsp;&nbsp;Derivative instruments | 82.8 |  | 82.8 |  |
| &nbsp;&nbsp;&nbsp;Contingent consideration | 12.3 |  |  | 12.3 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Carrying Value at September 30, 2025** | **Fair Value at September 30, 2025**<br>**Using Inputs Considered as:** | **Fair Value at September 30, 2025**<br>**Using Inputs Considered as:** | **Fair Value at September 30, 2025**<br>**Using Inputs Considered as:** |
| | **Carrying Value at September 30, 2025** | **Level 1** | **Level 2** | **Level 3** |
| Assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $164.8 | $164.8 | $— | $— |
| &nbsp;&nbsp;&nbsp;DPP receivables | 3.7 |  | 3.7 |  |
| &nbsp;&nbsp;&nbsp;Restricted cash | 0.6 | 0.6 |  |  |
| &nbsp;&nbsp;&nbsp;Restricted cash for benefit plan contributions | 26.0 | 26.0 |  |  |
| &nbsp;&nbsp;&nbsp;Investments in rabbi trust | 6.2 | 6.2 |  |  |
| &nbsp;&nbsp;&nbsp;Derivative instruments | 12.5 |  | 12.5 |  |
| Liabilities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Revolving credit facility | 225.0 |  | 225.0 |  |
| &nbsp;&nbsp;$175 term loan | 175.0 |  | 175.0 |  |
| &nbsp;&nbsp;€240 term loan | 281.3 |  | 281.3 |  |
| &nbsp;&nbsp;$350 senior unsecured notes | 350.0 | 329.9 |  |  |
| &nbsp;&nbsp;$500 senior unsecured notes | 500.0 | 513.4 |  |  |
| &nbsp;&nbsp;&nbsp;Derivative instruments | 81.3 |  | 81.3 |  |
| &nbsp;&nbsp;&nbsp;Contingent consideration | 14.2 |  |  | 14.2 |

---

------

***Valuation techniques***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash and cash equivalents, restricted cash, restricted cash for benefit plan contributions, and investments in rabbi trust are classified within Level 1 of the fair value hierarchy. Financial instruments classified as Level 1 are based on quoted market prices in active markets. The types of financial instruments the Company classifies within Level 1 include most bank deposits, money market securities, and publicly traded mutual funds. The Company does not adjust the quoted market price for such financial instruments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The DPP receivables fair value is based on a discounted cash flow analysis (estimated amount expected to be received) using historical experience and inputs from similar programs, which include the estimated timing of payments and the credit quality of the underlying creditor. Significant changes in any of the inputs in isolation would not result in a materially different fair value estimate. Based on the short-term nature of the DPP receivables, typically 90 -120 days, they are classified as a level 2 measurement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Company estimates the fair value of foreign currency derivatives using industry accepted models. The significant Level 2 inputs used in the valuation of derivatives include spot rates, forward rates, and volatility. These inputs were obtained from pricing services, broker quotes, and other sources.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The fair values of the amounts outstanding under the Facility, $175 term loan, and €240 term loan approximate carrying value, as the Company believes their variable interest rate terms correspond to current market terms, and therefore, are classified within Level 2 of the fair value hierarchy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The fair values of the $350 senior unsecured notes, and $500 senior unsecured notes were based on quoted prices in active markets and are classified within Level 1 of the fair value hierarchy. The Company does not adjust the quoted market prices for such financial instruments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The contingent consideration reflects the estimated fair value of contingent future cash payments to the previous owners of Schenck Process Food and Performance Materials ("FPM") for research and development tax credits that were generated by FPM prior to the acquisition date. The Company estimated the fair value of the contingent consideration based on the technical merits of the research and development tax credits using an internally developed analysis. The key inputs to this calculation include the nature of the research and development activities, personnel involved in the research and development activities, the level of research and development spend prior to acquisition by the Company, and interpretation of applicable tax law. The value of these credits is subject to audit by the tax authorities and to the closing of the statute of limitations for the year in which the tax credits are fully utilized, the timing of which is not able to be determined at this time, but we expect to extend several years. The inputs for the liability are unobservable, and therefore, are classified within Level 3 of the fair value hierarchy.

***Derivative instruments***

Hillenbrand participates in cross-currency swap agreements aiming to hedge the variability in the movement of foreign currency exchange rates for its operations in Europe, while simultaneously lowering the Company's overall borrowing costs. The maturity dates of these agreements range from 2027 to 2029. These agreements qualify for hedge accounting and accordingly the changes in the fair value of the derivatives are recorded in other comprehensive (loss) income and remain in accumulated other comprehensive loss attributable to Hillenbrand in shareholders' equity until the hedged item is recognized in earnings. We assess the effectiveness of cross-currency swap contracts using the spot method, and the difference between the interest rate received and paid under the cross-currency swap agreements is recorded in interest expense, net, in the Consolidated Statements of Operations. As a result of participating in these cross-currency swap agreements, Hillenbrand recorded a reduction in interest expense, net of $2.7 and $3.2 during the three months ended December 31, 2025 and 2024, respectively. Hillenbrand presents the cross-currency swap agreements' periodic settlements in operating activities in the Consolidated Statements of Cash Flows.

The Company has hedging programs in place to manage its currency exposures. The objectives of the Company's hedging programs are to mitigate exposures in gross margin and non-functional-currency-denominated assets and liabilities. Under these programs, the Company uses derivative financial instruments to manage the economic impact of fluctuations in currency exchange rates. These include foreign currency exchange forward contracts, which generally have terms up to 24 months.

The aggregate notional value of the cross-currency swap agreements was $781.5 and $778.0 at December 31, 2025 and September 30, 2025, respectively. The aggregate notional value of the foreign currency exchange forward contract derivatives was $371.7 and $365.3 at December 31, 2025 and September 30, 2025, respectively. The derivatives are recorded at fair value in prepaid expenses and other current assets, other current liabilities, and other long-term liabilities in the Consolidated Balance Sheets.

------

15.<u>Segment and Geographical Information</u>

Hillenbrand is composed of two reportable operating segments: Advanced Process Solutions and Molding Technology Solutions. The Company's reportable operating segments maintain separate financial information for which results of operations are evaluated on a regular basis by the Company's chief operating decision maker ("CODM") in deciding how to allocate resources and in assessing performance.

The Company's CODM is the Chief Executive Officer. The Company's CODM evaluates the performance of the operating segments and allocates resources to them based on Adjusted EBITDA. Adjusted EBITDA is the Company's measure of segment performance.

The Company records the direct costs of business operations to the reportable operating segments, including stock-based compensation, asset impairments, restructuring activities, and business acquisition costs. Corporate provides management and administrative services to each reportable operating segment. These services include treasury management, human resources, legal, business development, information technology, tax compliance, global supply management, sustainability, and other public company support functions such as internal audit, investor relations, and financial reporting. With limited exception for certain professional services and back-office and technology costs, the Company does not allocate these types of corporate expenses to the reportable operating segments.

Financial information for the Company's reportable operating segments is presented below.

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** |
| | **Advanced Process Solutions** | **Molding Technology Solutions** | **Corporate** | **Total** |
| Net revenue | $463.6 | $86.6 | $— | $550.2 |
| Segment cost of goods sold | 312.6 | 54.0 |  | 366.6 |
| Adjusted other segment expenses <sup>(1)</sup> | 90.6 | 16.4 | 14.5 | 121.5 |
| Segment adjusted EBITDA | $60.4 | $16.2 | $(14.5) | $62.1 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** |
| | **Advanced Process Solutions** | **Molding Technology Solutions** | **Corporate** | **Total** |
| Net revenue | $511.1 | $195.8 | $— | $706.9 |
| Segment cost of goods sold | 335.4 | 136.6 |  | 472.0 |
| Adjusted other segment expenses <sup>(1)</sup> | 92.9 | 31.8 | 13.1 | 137.8 |
| Segment adjusted EBITDA | $82.8 | $27.4 | $(13.1) | $97.1 |

---

<sup>(1)</sup> Adjusted other segment expenses consists primarily of segment selling, general and administrative expenses.

The following tables present financial information for the Company's reportable operating segments and significant geographical locations:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended December 31,** | **Three Months Ended December 31,** |
|  | **2025** | **2024** |
| **Net revenue** |  |  |
| &nbsp;&nbsp;&nbsp;Advanced Process Solutions | $463.6 | $511.1 |
| &nbsp;&nbsp;&nbsp;Molding Technology Solutions | 86.6 | 195.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $550.2 | $706.9 |
| **Adjusted EBITDA** <sup>(1)</sup> |  |  |
| &nbsp;&nbsp;&nbsp;Advanced Process Solutions | $60.4 | $82.8 |
| &nbsp;&nbsp;&nbsp;Molding Technology Solutions | 16.2 | 27.4 |
| &nbsp;&nbsp;&nbsp;Corporate | (14.5) | (13.1) |
| **Net revenue** <sup>(2)</sup> |  |  |
| &nbsp;&nbsp;&nbsp;United States | $183.3 | $284.7 |
| &nbsp;&nbsp;&nbsp;China | 72.6 | 81.1 |
| &nbsp;&nbsp;&nbsp;India | 28.5 | 57.1 |
| &nbsp;&nbsp;&nbsp;Germany | 51.7 | 51.1 |
| &nbsp;&nbsp;&nbsp;All other countries | 214.1 | 232.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $550.2 | $706.9 |

---

<sup>(1)</sup> Adjusted earnings before interest, income tax, depreciation, and amortization ("adjusted EBITDA") is a non-GAAP financial measure used by management to measure segment performance and make operating decisions.

<sup>(2)</sup> The Company attributes net revenue to a geography based upon the location of the end customer.

------

---

| | | |
|:---|:---|:---|
| | **December 31, 2025** | **September 30, 2025** |
| **Total assets** | | |
| &nbsp;&nbsp;&nbsp;Advanced Process Solutions | $3392.7 | $3438.1 |
| &nbsp;&nbsp;&nbsp;Molding Technology Solutions | 846.9 | 824.7 |
| &nbsp;&nbsp;&nbsp;Corporate | 229.5 | 204.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $4469.1 | $4467.1 |
| **Tangible long-lived assets, net** |  |  |
| &nbsp;&nbsp;&nbsp;United States | $83.1 | $86.1 |
| &nbsp;&nbsp;&nbsp;Germany | 122.6 | 125.9 |
| &nbsp;&nbsp;&nbsp;China | 44.4 | 42.1 |
| &nbsp;&nbsp;&nbsp;India | 12.3 | 6.6 |
| &nbsp;&nbsp;&nbsp;All other foreign business units | 79.3 | 81.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $341.7 | $342.6 |

---

The following schedule reconciles reportable operating segment adjusted EBITDA to consolidated net income:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
|  | **2025** | **2024** |
| Adjusted EBITDA: |  |  |
| &nbsp;&nbsp;Advanced Process Solutions | $60.4 | $82.8 |
| &nbsp;&nbsp;&nbsp;Molding Technology Solutions | 16.2 | 27.4 |
| &nbsp;&nbsp;&nbsp;Corporate | (14.5) | (13.1) |
| Less: |  |  |
| &nbsp;&nbsp;Interest expense, net | 20.2 | 25.1 |
| &nbsp;&nbsp;Income tax (benefit) expense | (12.9) | 6.4 |
| &nbsp;&nbsp;Depreciation and amortization | 33.1 | 37.9 |
| &nbsp;&nbsp;Pension settlement gain |  | (1.7) |
| &nbsp;&nbsp;Business acquisition, divestiture, and integration costs | 7.9 | 18.1 |
| &nbsp;&nbsp;Non-cash and non-operational expense related to equity method investment | 4.5 |  |
| &nbsp;&nbsp;Restructuring and restructuring-related charges | 4.9 | 2.4 |
| &nbsp;&nbsp;Loss on divestiture | 3.4 |  |
| Consolidated net income | $1.0 | $8.9 |

---

------

**Item 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*(financial amounts in millions, except share and per share data, throughout Management's Discussion and Analysis)*

**FORWARD-LOOKING STATEMENTS AND FACTORS THAT MAY AFFECT FUTURE RESULTS**

Throughout this Quarterly Report on Form 10-Q, we make a number of "forward-looking statements," including statements that are within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and that are intended to be covered by the safe harbor provided under these sections. These are statements about future sales, earnings, cash flow, results of operations, uses of cash, financings, share repurchases, ability to meet deleveraging goals, and other measures of financial performance or potential future plans or events, strategies, objectives, beliefs, prospects, assumptions, expectations, and projected costs or savings or transactions of the Company, including the proposed acquisition of Hillenbrand by an affiliate of Lone Star Fund XII, L.P. through a merger transaction (the "Merger"), that might or might not happen in the future, as contrasted with historical information. Forward-looking statements are based on assumptions that we believe are reasonable, but by their very nature are subject to a wide range of risks. If our assumptions prove inaccurate or unknown risks and uncertainties materialize, actual results could vary materially from Hillenbrand's expectations and projections.

The following list, though not exhaustive, contains words that could indicate a forward-looking statement.

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| intend | believe | plan | expect | may | goal | would | project | position | future | outlook |
| become | pursue | estimate | will | forecast | continue | could | anticipate | remain | likely | |
| target | encourage | promise | improve | progress | potential | should | impact | strategy | assume | |

---

Any number of factors, many of which are beyond our control, could cause our performance to differ significantly from what is described in the forward-looking statements. These factors include, but are not limited to: the risk that the Merger may not be consummated in a timely manner or at all; the possible inability of the parties to the definitive agreement for the Merger (the "Merger Agreement") to satisfy the conditions to the closing of the Merger, on a timely basis or at all; the possible occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; the risk that the Merger Agreement may be terminated in circumstances that require Hillenbrand to pay a termination fee; the risk that the relevant affiliates of Lone Star Funds fail to obtain on a timely basis or at all the financing necessary to complete the Merger; litigation relating to the Merger and the outcome of any such litigation, the potential adverse impact on Hillenbrand of contractual restrictions under the Merger Agreement that limit Hillenbrand's ability to pursue business opportunities or strategic transactions; risks relating to significant transaction costs associated with the Merger and the possibility that the Merger may be more expensive to complete than anticipated; competitors' responses to the Merger; global market and economic conditions, including those related to the continued volatility in the financial markets, including as a result of the United States ("U.S.") administration's imposition of tariffs and changing trade policies; the risk of business disruptions associated with information technology, cyber-attacks, or catastrophic losses affecting infrastructure; increasing competition for highly skilled and talented workers, as well as labor shortages; closures or slowdowns and changes in labor costs and labor difficulties; uncertainty related to environmental regulation and industry standards, as well as physical risks of climate change; increased costs, poor quality, or unavailability of raw materials or certain outsourced services and supply chain disruptions; economic and financial conditions including volatility in interest and exchange rates, commodity and equity prices and the value of financial assets; uncertainty in U.S. global trade policy and risks with governmental instability in certain parts of the world; our level of international sales and operations; negative effects of acquisitions, including the Schenck Process Food and Performance Materials business and Linxis Group SAS acquisitions, on the Company's business, financial condition, results of operations and financial performance; competition in the industries in which we operate, including on price; cyclical demand for industrial capital goods; the ability to recognize the benefits of any acquisition or divestiture, including the sale of Milacron injection molding and extrusion business (the "Disposition"), including potential synergies and cost savings or the failure of the Company or any acquired company, or the Disposition, to achieve its plans and objectives generally; any strategic and operational initiatives implemented by the parties to the Disposition after the consummation of the Disposition; potential adverse effects of the announcement or results of the Disposition or the announcement or pendency of the Merger, or any failure to complete the Merger, on the market price of the Company's common stock or on the ability of the Company to develop and maintain relationships with its personnel and customers, suppliers and others with whom it does business or otherwise on the Company's business, financial condition, results of operations and financial performance; risks related to diversion of management's attention from our ongoing business operations due to the Disposition or the Merger; impairment charges to goodwill and other identifiable intangible assets; impacts of decreases in demand or changes in technological advances, laws, or regulation on the net revenues that we derive from the plastics industry; the impact to the Company's effective tax rate of changes in the mix of earnings or in tax laws and

------

certain other tax-related matters; exposure to tax uncertainties and audits; involvement in claims, lawsuits, and governmental proceedings related to operations; uncertainty in the U.S. political and regulatory environment; adverse foreign currency fluctuations; and labor disruptions. There can be no assurances that the Merger will be consummated.

Shareholders, potential investors, and other readers are urged to consider these risks and uncertainties in evaluating forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. For a more in-depth discussion of certain factors that could cause actual results to differ from those contained in forward-looking statements, see the discussion under the heading "Risk Factors" in Part I, Item 1A of Hillenbrand's Form 10-K for the year ended September 30, 2025, filed with the Securities and Exchange Commission (the "SEC") on November 19, 2025, as well as other risks and uncertainties detailed in our other filings with the SEC from time to time. Any forward-looking statement made in this Quarterly Report on Form 10-Q is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update or revise any forward-looking statement, whether written or oral, made to reflect new information, future developments or otherwise.

**EXECUTIVE OVERVIEW**

Hillenbrand (www.Hillenbrand.com) is a global industrial company that provides highly-engineered processing equipment and solutions to customers around the world. Our portfolio is composed of leading industrial brands that serve large, attractive end markets, including durable plastics, food, and recycling. Guided by our Purpose, Shape What Matters for Tomorrow<sup>TM</sup>, we pursue excellence, collaboration, and innovation to shape solutions that best serve our people, our customers, and our communities. Customers choose Hillenbrand due to our reputation for designing, manufacturing, and servicing highly-engineered, mission-critical equipment and solutions that meet their unique and complex processing requirements.

***Acquisition by Lone Star***

As announced on October 15, 2025, on October 14, 2025, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement") with LSF12 Helix Parent, LLC, a Delaware limited liability company ("Parent"), and LSF12 Helix Merger Sub, Inc., an Indiana corporation and a wholly owned subsidiary of Parent ("Merger Sub"), providing for the merger of Merger Sub with and into Hillenbrand (the "Merger"), with Hillenbrand surviving the Merger as a wholly owned subsidiary of Parent. Parent and Merger Sub are affiliates of Lone Star Funds XII, L.P.

At the effective time of the Merger, on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Company's common stock issued and outstanding immediately prior to such time, other than shares of the Company's common stock owned by Hillenbrand, any wholly owned subsidiary of Hillenbrand, Parent, Merger Sub or any other wholly owned subsidiary of Parent (each of which will be cancelled), will be converted into the right to receive $32.00 in cash, without interest.

The transactions contemplated by the Merger Agreement were unanimously approved by Hillenbrand's Board of Directors, and Hillenbrand's shareholders voted to approve the Merger Agreement at a special meeting of the Company's shareholders on January 8, 2026. The Merger is expected to close by the end of the first quarter of calendar year 2026, subject to customary closing conditions.

***Divestiture of Milacron***

On March 31, 2025, the Company completed the divestiture of its majority interest in the Milacron injection molding and extrusion business ("Milacron") pursuant to the Contribution and Purchase Agreement ("Agreement") between the Company and an affiliate of Bain Capital ("Bain"). In accordance with the terms of the Agreement, Hillenbrand contributed $222.6 of net assets of Milacron, and its wholly-owned subsidiaries, to a newly formed limited liability company, Milacron Holdings, LLC ("Milacron Holdings"). Hillenbrand retained a 48.74% minority ownership of Milacron Holdings upon contribution of Milacron. Hillenbrand received total consideration of $286.0 for its contribution of Milacron. The total consideration was comprised of $98.0 of cash proceeds paid by Bain and $188.0 of debt assumed by Bain (as described below), in exchange for obtaining a 51.26% majority ownership of Milacron Holdings.

In connection with the closing of the transactions contemplated by the Agreement, certain wholly-owned subsidiaries of Milacron entered into a long-term credit agreement with Midcap Financial Trust, which included initial term loans in an aggregate principal amount of $188.0, which were then assumed by Bain as described above. The maturity date of the long-term credit agreement is March 31, 2032 and includes standard financial and non-financial covenants. The long-term credit agreement also included revolving credit loans available to certain wholly-owned subsidiaries of Milacron not to exceed $30.0.

------

As a result of the Milacron divestiture, the Company recorded a pre-tax loss of $57.2, after post-closing adjustments, in the Consolidated Statement of Operations during year ended September 30, 2025. The Company incurred $8.9 of transaction costs associated with the divestiture during the year ended September 30, 2025, which were recorded within the Molding Technology Solutions reportable operating segment. Upon the divestiture of Milacron, the Company's equity interest in Milacron Holdings is accounted for under the equity method of accounting as prescribed by GAAP.

**OPERATING PERFORMANCE MEASURES**

The following discussion compares our results for the three months ended December 31, 2025, to the same period in 2024. The Company's fiscal year ends on September 30. Unless otherwise stated, references to years refer to fiscal years. We begin the discussion at a consolidated level and then provide separate detail about Advanced Process Solutions, Molding Technology Solutions, and Corporate. These results of operations are prepared in accordance with GAAP.

We also provide certain non-GAAP operating performance measures. These non-GAAP financial measures are referred to as "adjusted" measures and generally exclude expenses associated with business acquisition, divestiture, and integration costs, restructuring and restructuring-related charges, pension settlement gain or charges, and inventory step-up costs.

Non-GAAP information is provided as a supplement to, not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP.

We use this non-GAAP information internally to measure operating segment performance and make operating decisions and believe it is helpful to investors because it allows more meaningful period-to-period comparisons of our ongoing operating results. The information can also be used to perform trend analysis and to better identify operating trends that may otherwise be masked or distorted by items such as the above excluded items. We believe this information provides a higher degree of transparency.

An important non-GAAP financial measure that we use is adjusted earnings before interest, income tax, depreciation, and amortization ("adjusted EBITDA"). A part of Hillenbrand's strategy is to selectively acquire companies that we believe can benefit from the Hillenbrand Operating Model ("HOM") to spur faster and more profitable growth. Given that strategy, it is a natural consequence to incur related expenses, such as amortization from acquired intangible assets and additional interest expense from debt-funded acquisitions. Accordingly, we use adjusted EBITDA, among other measures, to monitor our business performance. Adjusted EBITDA is not a recognized term under GAAP and therefore does not purport to be an alternative to net income. Further, the Company's measure of adjusted EBITDA may not be comparable to similarly titled measures of other companies.

Another important operational measure used is backlog. Backlog is not a term recognized under GAAP; however, it is a common measurement used in industries with extended lead times for order fulfillment (long-term contracts), like those in which our reportable operating segments compete. Backlog represents the amount of net revenue that we expect to realize on contracts awarded to our reportable operating segments. For purposes of calculating backlog, 100% of estimated net revenue attributable to consolidated subsidiaries is included. Backlog includes expected net revenue from large systems and equipment, as well as aftermarket parts, components, and service. The length of time that projects remain in backlog can span from days for aftermarket parts or service to approximately 18 to 24 months for larger system sales within the Advanced Process Solutions reportable operating segment. The majority of the backlog within the Molding Technology Solutions reportable operating segment is expected to be fulfilled within the next twelve months. Backlog includes expected net revenue from the remaining portion of firm orders not yet completed, as well as net revenue from change orders to the extent that they are reasonably expected to be realized. We include in backlog the full contract award, including awards subject to further customer approvals, which we expect to result in net revenue in future periods. In accordance with industry practice, our contracts may include provisions for cancellation, termination, or suspension at the discretion of the customer.

We expect that future net revenue associated with our reportable operating segments will be influenced by order backlog because of the lead time involved in fulfilling engineered-to-order equipment for customers. Although backlog can be an indicator of future net revenue, it does not include projects and parts orders that are booked and shipped within the same quarter. The timing of order placement, size, extent of customization, and customer delivery dates can create fluctuations in backlog and net revenue. Net revenue attributable to backlog may also be affected by foreign exchange fluctuations for orders denominated in currencies other than U.S. dollars.

We calculate the foreign currency impact on net revenue, gross profit, selling, general and administrative expenses, backlog, consolidated net income, and adjusted EBITDA in order to better measure the comparability of results between periods. We

------

calculate the foreign currency impact by translating current year results at prior year foreign exchange rates. This information is provided because exchange rates can distort the underlying change in these metrics, either positively or negatively. The cost structure for Corporate is generally not significantly impacted by the fluctuation in foreign exchange rates, and we do not disclose the foreign currency impact in the Operations Review section below where the impact is not significant.

See page 24 for a reconciliation of adjusted EBITDA to consolidated net income, the most directly comparable GAAP financial measure. We use other non-GAAP financial measures in certain other instances and include information reconciling such non-GAAP financial measures to the respective most directly comparable GAAP financial measures. Given that backlog is an operational measure and that the Company's methodology for calculating backlog does not meet the definition of a non-GAAP financial measure, as that term is defined by the SEC, a quantitative reconciliation is not required or provided.

**CRITICAL ACCOUNTING ESTIMATES**

For the three months ended December 31, 2025, there were no significant changes to our critical accounting estimates as outlined in our Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on November 19, 2025.

**<u>OPERATIONS REVIEW — CONSOLIDATED</u>**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** |
| | **2025** | **2025** | **2024** | **2024** |
| | **Amount** | **% of Net<br>Revenue** | **Amount** | **% of Net<br>Revenue** |
| Net revenue | $550.2 |  | $706.9 | 100.0 |
| Gross profit | 183.7 | 33.4 | 235.0 | 33.2 |
| <br>Selling, general and administrative expenses | 149.2 | 27.1 | 171.1 | 24.2 |
| Amortization expense | 22.8 |  | 25.2 |  |
| Loss on divestiture | 3.4 |  |  |  |
| Pension settlement gain |  |  | (1.7) |  |
| Interest expense, net | 20.2 |  | 25.1 |  |
| Income tax (benefit) expense | (12.9) |  | 6.4 |  |

---

***Three Months Ended December 31, 2025 Compared to Three Months Ended December 31, 2024***

**<u>Net revenue</u>** decreased $156.7 (22%).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Advanced Process Solutions net revenue decreased $47.5 (9%), primarily driven by a decrease in capital equipment sales volume and lower aftermarket parts and service net revenue, partially offset by favorable pricing. Foreign currency impact increased net revenue by 4%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Molding Technology Solutions net revenue decreased $109.2 (56%), primarily driven by the divestiture of Milacron. Foreign currency impact increased net revenue by 1%.

**<u>Gross profit</u>** decreased $51.3 (22%) and gross profit margin improved 20 basis points to 33.4%. On an adjusted basis, which excludes business acquisition, divestiture, and integration costs and restructuring and restructuring-related charges, adjusted gross profit decreased $50.2 (21%), and adjusted gross profit margin improved 40 basis points to 33.8%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Advanced Process Solutions gross profit decreased $24.6 (14%), primarily driven by lower volume, unfavorable product mix, and cost inflation, partially offset by favorable pricing and productivity improvements. Gross profit margin decreased 180 basis points to 32.6%,

Advanced Process Solutions gross profit included restructuring and restructuring related charges ($1.8 in 2026 and $0.8 in 2025). Excluding these non-recurring items, adjusted gross profit decreased $23.6 (13%) and adjusted gross profit margin decreased 150 basis points to 33.0%.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Molding Technology Solutions gross profit decreased $26.7 (45%) primarily driven by the divestiture of Milacron. Foreign currency impact improved gross profit by 1%. Gross profit margin increased 730 basis points to 37.6%,

**<u>Selling, general and administrative expenses</u>** decreased $21.9 (13%), primarily driven by the divestiture of Milacron, a decrease in variable compensation, a decrease in business acquisition, divestiture, and integration costs, and productivity improvements, partially offset by cost inflation. Foreign currency impact increased selling, general and administrative expenses by 1%. Selling, general and administrative expenses as a percentage of net revenue increased 290 basis points to 27.1%. Selling, general and administrative expenses included the following items:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** |
| | **2025** | **2024** |
| Business acquisition, divestiture, and integration costs | $7.9 | $18.1 |
| Restructuring and restructuring-related charges | 2.8 | 1.4 |

---

On an adjusted basis, which excludes business acquisition, divestiture, and integration costs and restructuring and restructuring-related charges, selling, general and administrative expenses decreased $17.6 (12%). Adjusted selling, general and administrative expenses as a percentage of net revenue increased 300 basis points to 24.4%.

**<u>Loss on divestiture</u>** of $3.4 was due to the loss on divestiture of Milacron.

**<u>Pension settlement gain</u>** decreased $1.7 due to one-time premium refunds received in 2025 from the termination of the Company's U.S. pension plan. See Note 8 of Part I, Item 1 of this Quarterly Report on Form 10-Q for further information on this pension settlement gain.

**<u>Interest expense, net</u>** decreased $4.9 (20%), primarily due to lower weighted average borrowings.

**<u>The effective tax rate</u>** was 108.4% in 2026 compared to 41.8% in 2025. The increase in the effective tax rate was primarily driven by one-time discrete impacts related to the finalization of the income tax accounting related to the sale of Milacron and related restructuring activities and the effect of the approval of an incentive reduced income tax rate for certain operations located in China, partially offset by the geographic mix of earnings.

**<u>OPERATIONS REVIEW — Advanced Process Solutions</u>**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** |
| | **2025** | **2025** | **2024** | **2024** |
| | **Amount** | **% of Net<br>Revenue** | **Amount** | **% of Net<br>Revenue** |
| Net revenue | $463.6 |  | $511.1 | 100.0 |
| Gross profit | 151.1 | 32.6 | 175.7 | 34.4 |
| Selling, general and administrative expenses | 102.6 | 22.1 | 109.0 | 21.3 |
| Amortization expense | 16.2 |  | 16.4 |  |

---

***Three Months Ended December 31, 2025 Compared to Three Months Ended December 31, 2024***

**<u>Net revenue</u>** decreased $47.5 (9%), primarily driven by a decrease in capital equipment sales volume and lower aftermarket parts and service net revenue, partially offset by favorable pricing. Foreign currency impact increased net revenue by 4%.

Order backlog decreased $150.9 (10%) from $1,583.6 at December 31, 2024, to $1,432.7 at December 31, 2025. The decrease in order backlog was primarily driven by a decrease in capital equipment orders. Foreign currency impact increased order backlog by 6%. On a sequential basis, order backlog decreased $89.7 (6%) to $1,432.7 at December 31, 2025, down from $1,522.4 at September 30, 2025, primarily driven by a decrease in capital equipment orders.

**<u>Gross profit</u>** decreased $24.6 (14%), primarily driven by lower volume, unfavorable product mix, and cost inflation, partially offset by favorable pricing and productivity improvements. Gross profit margin decreased 180 basis points to 32.6%,

------

Advanced Process Solutions gross profit included restructuring and restructuring related charges ($1.8 in 2026 and $0.8 in 2025). Excluding these non-recurring items, adjusted gross profit decreased $23.6 (13%) and adjusted gross profit margin decreased 150 basis points to 33.0%.

**<u>Selling, general and administrative expenses</u>** decreased $6.4 (6%) primarily driven by a decrease in variable compensation and productivity improvements, partially offset by cost inflation. Selling, general and administrative expenses as a percentage of net revenue increased 80 basis points to 22.1%.

Selling, general and administrative expenses included business acquisition, divestiture, and integration costs ($0.9 in 2026 and $7.1 in 2025) and restructuring and restructuring-related charges ($2.5 in 2026 and $0.7 in 2025). Excluding these items, adjusted selling, general and administrative expenses decreased $1.9 (2%) and adjusted selling, general and administrative expenses as a percentage of net revenue increased 160 basis points to 21.4%.

**<u>OPERATIONS REVIEW — Molding Technology Solutions</u>**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** |
| | **2025** | **2025** | **2024** | **2024** |
| | **Amount** | **% of Net<br>Revenue** | **Amount** | **% of Net<br>Revenue** |
| Net revenue | $86.6 | 100.0 | $195.8 | 100.0 |
| Gross profit | 32.6 | 37.6 | 59.3 | 30.3 |
| Selling, general and administrative expenses | 19.6 | 22.6 | 41.4 | 21.1 |
| Amortization expense | 6.6 |  | 8.8 |  |

---

***Three Months Ended December 31, 2025 Compared to Three Months Ended December 31, 2024***

**<u>Net revenue</u>** decreased $109.2 (56%), primarily driven by the divestiture of Milacron. Foreign currency impact increased net revenue by 1%.

Order backlog decreased $179.1 (77%) from $233.1 at December 31, 2024, to $54.0 at December 31, 2025, primarily due to the Milacron divestiture. On a sequential basis, order backlog increased $2.2 (4%) to $54.0 at December 31, 2025, up from $51.8 at September 30, 2025.

**<u>Gross profit</u>** decreased $26.7 (45%) primarily driven by the divestiture of Milacron. Foreign currency impact improved gross profit by 1%. Gross profit margin increased 730 basis points to 37.6%,

**<u>Selling, general and administrative expenses</u>** decreased $21.8 (53%), primarily driven the divestiture of Milacron. Selling, general and administrative expenses as a percentage of net revenue increased 150 basis points to 22.6%.

Selling, general and administrative expenses included business acquisition, divestiture, and integration costs ($4.0 in 2025) and restructuring and restructuring related costs ($0.3 in 2026 and $0.7 in 2025). Excluding these charges, adjusted selling, general and administrative expenses decreased $17.6 (48%) and adjusted selling, general and administrative expenses as a percentage of net revenue increased 340 basis points to 22.2%.

------

**<u>REVIEW OF CORPORATE EXPENSES</u>**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** |
| | **2025** | **2025** | **2024** | **2024** |
| | **Amount** | **% of Net Revenue** | **Amount** | **% of Net Revenue** |
| Core corporate expenses | $15.5 | 2.8 | $13.7 | 1.9 |
| Business acquisition, divestiture, and integration costs | 7.0 | 1.3 | 7.0 | 1.0 |
| Non-cash and non-operational expense related to equity method investment | 4.5 | 0.8 |  |  |
| Corporate expenses | $27.0 | 4.9 | $20.7 | 2.9 |

---

Corporate expenses include the cost of providing management and administrative services to each reportable operating segment. These services include treasury management, human resources, legal, business development, information technology, tax compliance, procurement, sustainability, and other public company support functions such as internal audit, investor relations, and financial reporting. Corporate expenses also include costs related to business acquisition, divestiture, and integration, which we incur as a result of our strategy to grow through selective acquisitions. Core expenses primarily represent corporate expenses excluding costs related to business acquisition, divestiture, and integration costs and restructuring and restructuring-related charges.

Business acquisition, divestiture, and integration costs include legal, tax, accounting, and other advisory fees and due diligence costs associated with investigating opportunities (including acquisitions and divestitures) and integrating completed acquisitions, and accelerating synergies and cost saving initiatives across the Company. These expenses are incurred in the Advanced Process Solutions and Molding Technology Solutions reportable operating segments, and at Corporate.

***Three Months Ended December 31, 2025 Compared to Three Months Ended December 31, 2024***

Corporate expenses increased $6.3 (30%), primarily driven by an increase in non-cash and non-operational expense related to equity method investments and a decrease in equity earnings from affiliates. These expenses as a percentage of net revenue were 4.9%, an increase of 200 basis points from the prior year.

Core corporate expenses increased $1.8 (13.1%), primarily due to a decrease in equity earnings from affiliates. These expenses as a percentage of net revenue were 2.8%, flat to prior year.

**<u>NON-GAAP OPERATING PERFORMANCE MEASURES</u>**

The following is a reconciliation from consolidated net income, the most directly comparable GAAP operating performance measure, to our non-GAAP adjusted EBITDA.

---

| | | |
|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** |
| | **2025** | **2024** |
| &nbsp;&nbsp;&nbsp;Consolidated net income | $1.0 | $8.9 |
| &nbsp;&nbsp;&nbsp;Interest expense, net | 20.2 | 25.1 |
| &nbsp;&nbsp;&nbsp;Income tax (benefit) expense | (12.9) | 6.4 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 33.1 | 37.9 |
| Consolidated EBITDA | 41.4 | 78.3 |
| &nbsp;&nbsp;Pension settlement gain <sup>(1)</sup> |  | (1.7) |
| &nbsp;&nbsp;Loss on divestiture <sup>(2)</sup> | 3.4 |  |
| &nbsp;&nbsp;Business acquisition, divestiture, and integration costs <sup>(3)</sup> | 7.9 | 18.1 |
| &nbsp;&nbsp;Non-cash and non-operational expense related to equity method investment <sup>(4)</sup> | 4.5 |  |
| &nbsp;&nbsp;Restructuring and restructuring-related charges <sup>(5)</sup> | 4.9 | 2.4 |
| Adjusted EBITDA | $62.1 | $97.1 |

---

<sup>(1)</sup> The pension settlement gain during the three months ended December 31, 2025, was due to one-time premium refunds received related to the termination of the Company's U.S. pension plan.

------

<sup>(2)</sup> The current year amount represents loss on the divestiture of Milacron.

<sup>(3)</sup> Business acquisition, divestiture, and integration costs during the three months ended December 31, 2025 and 2024. The costs incurred during the three months ended December 31, 2025, primarily included costs associated with the Merger. The costs incurred during the three months ended December 31, 2024, primarily included costs associated with the integration of recent acquisitions.

<sup>(4)</sup> Inventory step-up costs related to equity method investment.

<sup>(5)</sup> Restructuring and restructuring-related charges primarily included severance costs during the three months ended December 31, 2025 and 2024.

***Three Months Ended December 31, 2025 Compared to Three Months Ended December 31, 2024***

Consolidated net income decreased $7.9 (89%) for the three months ended December 31, 2025, compared to the same period in fiscal 2025. The decrease was primarily driven by lower volume and cost inflation, partially offset by a decrease in business acquisition, divestiture, and integration costs, a decrease in income tax expense, favorable pricing, and productivity improvements.

Consolidated adjusted EBITDA decreased $35.0 (36%) for the three months ended December 31, 2025, compared to the same period in fiscal 2025. The decrease was primarily driven by the divestiture of Milacron, lower volume, and cost inflation, partially offset by favorable pricing and productivity improvements. Foreign currency impact increased adjusted EBITDA by $1.7 (2%).

**<u>LIQUIDITY AND CAPITAL RESOURCES</u>**

**Ability to Access Cash**

Our debt financing has historically included revolving credit facilities, term loans, and long-term notes as part of our overall financing strategy. We regularly review and adjust the mix of fixed-rate and variable-rate debt within our capital structure in order to achieve a target range based on our financing strategy.

As of December 31, 2025, we had $400.7 of borrowing capacity under the Facility, of which $34.5 was available as of such date based on our most restrictive covenant. The available borrowing capacity as of December 31, 2025, reflected a reduction of $15.8 for outstanding letters of credit issued under the Facility. The Company may request an increase of up to $600.0 in the total borrowing capacity under the Facility, subject to approval of the lenders.

In the normal course of business, operating companies within our reportable operating segments provide to certain customers bank guarantees and other credit arrangements in support of performance, warranty, advance payment, and other contractual obligations. This form of trade finance is customary in the industry and, as a result, we maintain adequate capacity to provide the guarantees. As of December 31, 2025, we had guarantee arrangements totaling $668.0, under which $363.3 was used for guarantees. These arrangements include the 2025 Amended L/G Facility Agreement under which unsecured letters of credit, bank guarantees, or other surety bonds may be issued. The Company may request an increase to the total capacity under the 2025 Amended L/G Facility Agreement by an additional €100.0, subject to approval of the lenders.

We have significant operations outside the U.S. We continue to assert that the basis differences in the majority of our foreign subsidiaries continue to be permanently reinvested outside of the U.S. We have recorded tax liabilities associated with distribution taxes on expected distributions of available cash and current earnings. The Company has made, and intends to continue to make, substantial investments in our businesses in foreign jurisdictions to support the ongoing development and growth of our international operations. The cash at our foreign subsidiaries, including U.S. subsidiaries participating in non-U.S. cash pooling arrangements, totaled $144.1 at December 31, 2025. We continue to actively evaluate our global capital deployment and cash needs.

On December 2, 2021, our Board of Directors authorized a new share repurchase program of up to $300.0, which replaced the previous $200.0 share repurchase program. The repurchase program has no expiration date but may be terminated by the Board of Directors at any time. We had approximately $125.0 remaining for share repurchases under the existing authorization at December 31, 2025. We are prohibited under the terms of the Merger Agreement from undertaking share repurchases except as agreed by Parent.

Our anticipated contribution to our defined benefit pension plans in fiscal 2026 is $10.1, of which $1.9 was made during the three months ended December 31, 2025. We will continue to monitor plan funding levels, performance of the assets within the

------

plans, and overall economic activity, and we may make additional discretionary funding decisions based on the net impact of the above factors.

We paid a quarterly cash dividend $0.2275 per common share, approximately $16.1 in the aggregate, during the three months ended December 31, 2025. We are prohibited under the terms of the Merger Agreement from paying any further dividends except as agreed by Parent.

We believe existing cash and cash equivalents, cash flows from operations, borrowings under existing arrangements, and the issuance of debt will be sufficient to fund our operating activities and cash commitments for investing and financing activities. Based on these factors, and assuming the Merger is consummated within the currently expected time frame, we believe our current liquidity position is sufficient and will continue to meet all of our financial commitments in the current business environment.

**Merger Agreement**

The Merger Agreement contains customary covenants regarding the conduct of the business of the Company and its subsidiaries prior to the closing of the Merger. In addition, pursuant to the Merger Agreement, the Company has agreed, subject to certain exceptions, not to take, authorize or agree or commit to do certain actions, including incurring indebtedness for borrowed money or guaranteeing any such indebtedness, or issuing or selling any debt securities or warrants or other rights to acquire any debt security of the Company or any of its subsidiaries. Notwithstanding the foregoing, the Merger Agreement permits the Company and its subsidiaries to incur indebtedness pursuant to agreements in effect prior to the execution of the Merger Agreement, including the agreement governing the Facility, the Amended L/G Facility Agreement and the indentures governing the Company's senior unsecured notes due February 2029 and the Company's senior unsecured notes due March 2031. The Merger Agreement also prohibits the aggregate principal amount of all outstanding letters of credit, bank guarantees, credit support instruments (other than surety bonds or similar instruments) or similar obligations in respect of the Company and/or any of its subsidiaries to exceed $350.0 in the aggregate at any time prior to the consummation of the Merger, subject to certain exceptions. We do not believe that these restrictions or other restrictions in the Merger Agreement will prevent us from meeting our debt obligations, ongoing costs of operations, working capital needs or capital expenditure requirements.

**<u>Cash Flows</u>**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** |
| | **2025** | **2024** |
| Cash flows (used in) provided by: |  |  |
| &nbsp;&nbsp;&nbsp;Operating activities | $(27.4) | $(11.3) |
| &nbsp;&nbsp;&nbsp;Investing activities | 1.4 | 9.5 |
| &nbsp;&nbsp;&nbsp;Financing activities | 31.2 | 26.8 |
| &nbsp;&nbsp;&nbsp;Effect of exchange rates on cash and cash equivalents | 1.7 | (14.4) |
| Net cash flows | $6.9 | $10.6 |

---

**<u>Operating Activities</u>**

Operating activities used $27.4 of cash during the three months ended December 31, 2025, and used $11.3 of cash during the three months ended December 31, 2024, a $16.1 decrease. The decrease in operating cash flow used was primarily driven by decreased order volume and unfavorable timing of working capital requirements.

Working capital requirements for our reportable operating segments fluctuate and may continue to fluctuate in the future due primarily to the type of product and geography of customer projects in process at any point in time. Working capital needs are lower when advance payments from customers are more heavily weighted toward the beginning of the project. Conversely, working capital needs are higher when a larger portion of the cash is to be received in later stages of manufacturing.

**<u>Investing Activities</u>**

The $8.1 decrease in net cash flows from investing activities during the three months ended December 31, 2025, was primarily due to the decrease in collection of deferred purchase price receivables as well as a decrease in proceeds from a cross currency swap settlement.

------

**<u>Financing Activities</u>** 

Cash used in financing activities was largely impacted by net borrowing activity. Our general practice is to use available cash to pay down debt unless it is needed for an acquisition. The $4.4 increase in net cash flows from financing activities during the three months ended December 31, 2025, was primarily due to the increase in net borrowings on the Facility.

We returned $16.1 to shareholders during the three months ended December 31, 2025 in the form of quarterly dividends. We increased our quarterly dividend in fiscal 2025 to $0.2275 per common share from $0.2250 per common share paid during fiscal 2025. Pursuant to the terms of the Merger Agreement, no additional cash dividends will be paid.

**Summarized Financial Information for Guarantors and the Issuer of Guaranteed Securities**

Summarized financial information of Hillenbrand (the "Parent") and our subsidiaries that are guarantors of our senior unsecured notes (the "Guarantor Subsidiaries") is shown below on a combined basis as the "Obligor Group." The Company's senior unsecured notes are guaranteed by certain of our wholly-owned domestic subsidiaries and rank equally in right of payment with all of our existing and financial information of the Obligor Group. All intercompany balances and transactions between the Parent and Guarantor Subsidiaries have been eliminated and all information excludes subsidiaries that are not issuers or guarantors of our senior unsecured notes, including earnings from and investments in these entities.

---

| | | |
|:---|:---|:---|
| | **December 31, 2025** | **September 30, 2025** |
| **Combined Balance Sheets Information:** | | |
| &nbsp;&nbsp;Current assets <sup>(1)</sup> | $1638.5 | $1968.0 |
| &nbsp;&nbsp;Non-current assets | 5757.1 | 5667.2 |
| &nbsp;&nbsp;Current liabilities | 1544.5 | 1575.7 |
| &nbsp;&nbsp;Non-current liabilities | 1337.6 | 1342.2 |
|  |  | **Three Months Ended<br>December 31, 2025** |
| **Combined Statements of Operations Information:** |  |  |
| &nbsp;&nbsp;Net revenue <sup>(2)</sup> |  | $93.9 |
| &nbsp;&nbsp;Gross profit |  | 33.3 |
| &nbsp;&nbsp;Net loss attributable to Obligors |  | (1.0) |

---

<sup>(1)</sup> Current assets include intercompany receivables from non-guarantors of $665.1 as of December 31, 2025 and $877.5 as of September 30, 2025.

<sup>(2)</sup> Net revenue includes intercompany sales with non-guarantors of $3.9 for the three months ended December 31, 2025.

**Recently Adopted and Issued Accounting Standards** 

For a summary of recently issued and adopted accounting standards applicable to us, see Item 1, Note 2 of Part I of this Form 10-Q.

**Item 3.**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

A full discussion of quantitative and qualitative disclosures about market risk may be found in Item 7A of our 2025 Form 10-K for the year ended September 30, 2025, filed with the SEC on November 19, 2025. There have been no material changes in this information since the filing of our 2025 Form 10-K.

**Item 4.**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **CONTROLS AND PROCEDURES**

------

Our management, with the participation of our President and Chief Executive Officer and our Interim Chief Financial Officer (the "Certifying Officers"), evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Based upon that evaluation, the Certifying Officers concluded that our disclosure controls and procedures as of the end of the period covered by this report are effective.

In the ordinary course of business, we review our system of internal control over financial reporting and make changes to our systems and processes to improve such controls and increase efficiency, while ensuring that we maintain an effective internal control environment. Changes may include such activities as implementing new, more efficient systems, automating manual processes, and updating existing systems.

There have been no changes in internal control over financial reporting identified in the evaluation for the quarter ended December 31, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act.

**PART II — OTHER INFORMATION**

**Item 1.**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **LEGAL PROCEEDINGS**

Information pertaining to legal proceedings can be found in Note 13 to the Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

**Item 1A.**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **RISK FACTORS**

For information regarding the risks we face, see the discussion under Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on November 19, 2025.

**Item 5.**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **OTHER INFORMATION**

(c) Rule 10b5-1 Trading Plans

During the three months ended December 31, 2025, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.

**Item 6.**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **EXHIBITS**

The exhibits filed with this report are listed below. In reviewing any agreements included as exhibits to this report, please remember that they are included to provide you with information regarding their terms and are not intended to provide any other factual or disclosure information about us or the other parties to the agreements. The agreements may contain representations and warranties by the parties to the agreements, including us. Except where explicitly stated otherwise, these representations and warranties have been made solely for the benefit of the other parties to the applicable agreement and:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• should not necessarily be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• may have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• may apply standards of materiality in a way that is different from what may be viewed as material to you or other investors; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments.

Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time.

------

---

| | | |
|:---|:---|:---|
| <u>[Exhibit 2.1](https://www.sec.gov/Archives/edgar/data/1417398/000119312525241524/d937700dex21.htm)</u> |  | Agreement and Plan of Merger, dated as of October 14, 2025, by and among Hillenbrand Inc., LSF12 Helix Parent, LLC and LSF12 Helix Merger Sub, Inc. (Incorporate by reference to Exhibit 2.1 to Current Report on Form 8-K filed October 15, 2025) |
| <u>[Exhibit 3.1](https://www.sec.gov/Archives/edgar/data/1417398/000110465920021734/tm207960d1_ex3-1.htm)</u> |  | Restated and Amended Articles of Incorporation of Hillenbrand, Inc., effective as of February 13, 2020 (Incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed February 14, 2020) |
| <u>[Exhibit 3.2](https://www.sec.gov/Archives/edgar/data/1417398/000141739824000137/ex-3220240331.htm)</u> |  | Amended and Restated Code of By-Laws of Hillenbrand, Inc., effective as of April 26, 2024 (Incorporated by reference to Exhibit 3.2 to Current Report on Form 10-Q filed April 30, 2024) |
| <u>[Exhibit 22](https://www.sec.gov/Archives/edgar/data/1417398/000162828025053207/ex222025930.htm)</u> |  | List of Guarantor Subsidiaries of Hillenbrand, Inc. (Incorporated by reference to Exhibit 22 to Annual Report on Form 10-K filed November 19, 2025) |
| <u>[Exhibit 31.1](ex-31120251231.htm)</u> | \* | Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| <u>[Exhibit 31.2](ex-31220251231.htm)</u> | \* | Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| <u>[Exhibit 32.1](ex-32120251231.htm)</u> | \* | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| <u>[Exhibit 32.2](ex-32220251231.htm)</u> | \* | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| Exhibit 101 |  | The following financial statements from the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2024, formatted in Inline XBRL: (i) Consolidated Statements of Operations, (ii) Consolidated Statements of Comprehensive Income, (iii) Consolidated Balance Sheets, (iv) Consolidated Statements of Cash Flows, (v) Consolidated Statements of Shareholders' Equity, and (vi) Condensed Notes to Consolidated Financial Statements, tagged as blocks of text and including detailed tags. |
| Exhibit 104 |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |

---

\*&nbsp;&nbsp;&nbsp;&nbsp;Filed herewith.

------

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **HILLENBRAND, INC.** | **HILLENBRAND, INC.** |
| Date: February 9, 2026 | By: | /s/ Megan A. Walke |
|  |  | Megan A. Walke |
|  |  | Interim Chief Financial Officer, Vice President, Corporate |
|  |  | Controller and Chief Accounting Officer |

---

## Exhibit 31.1

**EXHIBIT 31.1**

CERTIFICATIONS

Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Kimberly K. Ryan, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Hillenbrand, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the periods covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a.)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b.)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 9, 2026

---

| |
|:---|
| /s/ Kimberly K. Ryan |
| Kimberly K. Ryan |
| President and Chief Executive Officer |

---

## Exhibit 31.2

**EXHIBIT 31.2**

CERTIFICATIONS

Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Megan A. Walke, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Hillenbrand, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the periods covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a.)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b.)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 9, 2026

---

| |
|:---|
| /s/ Megan A. Walke |
| Megan A. Walke |
| Interim Chief Financial Officer, Vice President, Corporate |
| Controller and Chief Accounting Officer |

---

## Exhibit 32.1

**EXHIBIT 32.1**

**Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of Hillenbrand, Inc. (the "Company") on Form 10-Q for the period ended December 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Kimberly K. Ryan, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| /s/ Kimberly K. Ryan |
| Kimberly K. Ryan |
| President and Chief Executive Officer |
| February 9, 2026 |

---

**A signed original of this written statement required by Section 906 has been provided to Hillenbrand, Inc. and will be retained by Hillenbrand, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.**

## Exhibit 32.2

**EXHIBIT 32.2**

**Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of Hillenbrand, Inc. (the "Company") on Form 10-Q for the period ended December 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Megan A. Walke, Interim Chief Financial Officer, Vice President, Corporate Controller and Chief Accounting Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| /s/ Megan A. Walke |
| Megan A. Walke |
| Interim Chief Financial Officer, Vice President, Corporate |
| Controller and Chief Accounting Officer |
| February 9, 2026 |

---

**A signed original of this written statement required by Section 906 has been provided to Hillenbrand, Inc. and will be retained by Hillenbrand, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.**

<br>